



# Index

- A**  
Abacavir, 158*nw*  
Abbott Diagnostics, 53–54  
Abbott Laboratories, 63, 71, 97,  
127, 151, 255  
AbbVie, 32, 63, 73–74, 97, 99,  
108–109, 109*nt*, 127, 192,  
411*b*–412*b*, 412*nn*, 413,  
413*b*  
AbbVie Ventures, 431  
Abciximab (ReoPro), 79  
Abecma (idecabtagene  
vicleucel), 307–308  
Abgenix, 75, 87*nv*, 297  
Acalabrutinib, 433  
Acetylcholinesterase inhibitors,  
108*nq*  
Acquisitions, 401–402, 411,  
414–415  
Actimmune, 19  
Actio Biosciences, 193,  
242–243, 243*nq*  
Activated cell therapy (ACT),  
295, 297, 304*nq*, 308  
Activist Investors, 239  
Acute dominant polycystic kidney  
disease (ADPKD), 266  
Acute lymphocytic leukaemia  
(ALL) cell therapy, 90, 91,  
177, 221*b*, 295, 305–306,  
305*ns*, 337  
Acute myeloid leukaemia  
(AML), 90, 223  
Adagio, 376*b*  
Adakveo (crizanlizumab), 287,  
288*b*  
Adalimumab (Humira), 32, 63,  
73–74, 97, 99, 411*b*, 413,  
413*b*  
Adams, Daniel (Dan), 8, 359  
Adams, Julian, 150  
Adaptare Biotherapeutics, 310*b*  
Adcentris (brentuximab  
vedotin), 90  
Adefovir (Hepsera), 260  
Adeno-associated viruses  
(AAVs), 275, 275*b*–276*b*,  
279–280, 282–283,  
289–293, 318, 320  
Adenosine deaminase deficiency,  
280, 281  
Adenovirus, 275, 275*b*, 277  
Adenovirus vectors, 365–366  
Adimab, 108*nr*, 376*b*  
Aducanumab (Aduhelm),  
105–106, 241*no*, 437  
Advanced Photon Source (APS),  
219, 219*nh*, Pl20  
Advent Life Sciences, 410  
Aera Therapeutics, 341*b*  
Afeyan, Noubar, 185*nbb*,  
367–368, 368*nq*, 427  
Affinia, 292  
Affinium, 220, 220*ni*  
Affymetrix, 145*b*, 176  
Afibcept, 118*b*  
Agalsidase beta, 237  
Age-related macular degeneration  
(AMD), 94, 267  
Ageing, 393–395, 394*b*  
Agios, 288*b*  
Agouron Pharmaceuticals, 213,  
213*na*  
Ajinomoto, 58  
Aldrich, Richard (Rich), 235,  
394*b*, 433  
Alecto, 108–109  
Alemtuzumab (CAMPATH 1),  
71, 71*ne*, 71*nf*, 150, 238,  
238*nj*  
Alexandria Real Estate Equities  
(ARE), 123, 406–409  
Alexion Pharmaceuticals, 245,  
245*b*, 369  
Alicaforsen, 254  
Alipogene tiparvovec, 282  
Alirocumab (Praluent), 118–119  
Allen, Paul, 218, 298  
Allison, James (Jim), 84, 100*nf*,  
403, 453  
Allogene, 308–309  
Allogeneic cells, 308  
Alnylam Pharmaceuticals, 120,  
262–266, 263*nn*, 263*no*,  
334, 436  
AlphaFold, 133, 214*nb*, 228–229  
ALPROLIX (Factor IX-Fc), 45,  
244, 425  
Altuviiiio, 45, 245, 246*nu*, 285  
ALZA, 62  
Alzheimer's disease (AD),  
103–108, 132, 133, 137,  
156, 209, 437  
AmBisome, 57, 259, 267  
American Cyanamid, 355  
American Home Products, 48  
Amersham International, 166*b*,  
185*nc*  
Amgen, 9, 9*nl*, 16, 37, 45–47,  
53–56, 63, 75, 91, 92, 119,  
125, 156, 190, 190*nkk*,  
211, 297, 304, 431, 435  
Amivantamab (Rybrevant), 92  
Amplifiable expression vectors, 22  
Amunix, 211  
Amvuttra (vutrisiran), 264  
AMX0035 (Relyvrio), 130–131,  
131*nc*  
Amylin Pharmaceuticals,  
122–123, 122*np*  
Amyloid hypothesis, 103–104,  
104*nl*, 107, 156  
Amyloid precursor protein  
(APP), 104–105, 156, 209  
Amyloidosis, hereditary  
transferrin-mediated, 264  
Amylyx, 130–131  
Amyotrophic lateral sclerosis  
(ALS), 108, 130–131,  
133–134, 193–194, 242,  
251, 255, 257  
Anadys, 266  
Ancestry.com, 157, 157*b*  
Anderson, Erikk, 108  
Anderson, William French, 276

Page numbers followed by *f* or *b* denote a figure or box respectively on the corresponding page. Page references for notes are shown as the page number followed by *n* and the individual note letter designation. References for Plates in the photo insert are listed by Pl#.

- Andrews, Sir Christopher, 357*b*  
Angiopoietin 2, 94  
Animal Virus Research Institute (AVRI), 27  
Ankara vaccinia virus, 365  
Antegren (natalizumab), 105  
Anthrax, 348  
Anti-ageing, 393–395, 394*b*  
Anti-CD38 mAb, 413*b*  
Anti-CTLA4 antibodies, 100*nf*, 101–102  
Anti-IL-12/23 mAb, 412*b*  
Anti-tumour necrosis factor (anti-TNF) antibody, 97–99, 98*nc*, 411*b*  
Antibodies, 29, 67*b*–68*b*, 68*f*, 72–75, 90–94, 97–110  
Antibody-drug conjugates (ADCs), 77, 89–90  
Antisense companies, 249–261  
Antisense oligonucleotides (ASOs), 115, 249, 253–257, 259, 263, 270  
Anzalone, Andrew, 338  
Apcel, 32  
Apolipoprotein B-100, 255  
Appaloosa Management, 434  
Applied Biosystems (ABI), 11*nq*, 42, 145*b*, 165, 166*b*, 184–186, 405*b*  
Aptamers, 267–268  
Arai, Ken-ichi, 62  
Aranesp, 55  
Arber, Werner, 180, 403, 451  
Arcalyst (Rilonacept), 117, 118*b*  
ARCH Venture Partners, 385, 388–393, 426, 427  
Arexvy, 365*b*  
ARIA (amyloid-related imaging abnormality), 105, 105*nm*  
Ariad Pharmaceuticals, 222, 222*ni*  
Arnold, Frances H., 394, 454  
Aromatic L-amino acid decarboxylase (AADC) deficiency, 288–289  
Arrakis, 269*b*  
Array Biopharma, 56  
Arris Pharmaceuticals, 144, 146–147, 157  
Artavanis-Tsakonas, Spyros, 202–206, P117  
Artificial intelligence (AI), 132–133, 228–230  
Arvinas, 395–397  
Aryl sulphatase deficiency, 281  
Ashrafian, Houman, 430–431  
Asilomar Conference, 5–7  
AskBio (Asklepios Biopharmaceutical), 292  
Association of Biotechnology Companies (ABC), 423  
Astellas Gene Therapies, 260*nk*, 282  
Astex, 217–218  
Astra AB, 148  
AstraZeneca, 32, 54, 91–92, 97*na*, 153, 245*b*, 255, 257, 361–362, 366, 368–369, 374–375, 374*nw*, 376*b*, 413  
Athena Neurosciences, 104–105  
Atlas Venture, 429–430, 429*b*  
Atripila, 260  
Attenuated vaccine, 348, 350–351, 350*b*, 361–362, 363  
Aurora Biosciences, 210, 233–236, 233*na*, 235*nb*–235*nc*, 436  
Australia antigen (AuAg), 352  
Avalon Ventures, 104, 126, 233  
Avastin (bevacizumab), 74  
Aventis SA, 150–151  
Avigen, 289  
Aviron, 361  
Avonex, 20, 85  
Axel, Richard, 35*nq*  
Axicabtagene ciloleucel (Yescarta), 304, 304*nr*. 306  
Axyx Pharmaceuticals, 101, 146–147, 192, P110  
**B**  
B-cell lymphoma, 192, 304, 304*nr*  
B-cell maturation antigen (BCMA), 306–307, 330  
Bacterial artificial chromosomes (BACs), 184  
Baculovirus vector system, 359  
Bain Capital, 128–129, 432  
Baker, David, 228, 229*b*  
Baker brothers, 433–434  
Balasubramanian, Shankar, 168  
Baldino, Frank, 127  
Baltimore, David, 36, 36*nt*, 343, 394, 451  
Bamlanivimab/etesevimab, 376*b*  
Bancel, Stéphane, 368, 368*nq*, 370  
Banting, Frederick, 10, 10*no*, 451  
Bapineuzumab (Bapi), 105, 105*nm*  
Barings, 32, 32*nk*  
Barkas, Alexander (Alex), 216, 218*ng*, 419  
Barrangou, Rodolphe, 324, 333  
Barré-Sinoussi, Françoise, 355, 452  
Barrett, Peter, 185  
Barron, Hal, 394  
Bartel, David, 262  
Base editing, 315, 325*f*, 327, 331–332, 335–340, 341, 342*b*  
BASF Pharma, 97  
Basic Local Alignment Search Tool (BLAST), 188*iii*  
Bauer, Daniel, 319  
Bavarian Nordic, 348, 348*na*  
Baxter, Allan, 115  
Baxter, John, 13  
Baxter Travenol, 35, 35*nr*, 37*nw*, 41, 44, 76  
Bayer, 44, 65, 99, 118*b*, 125, 149–150, 292, 331  
Bayh–Dole Act, 53, 177, 402–403  
Bayley, Hagan, 172  
Bazell, Robert, 87–88  
BCL11A gene, 315, 319–320, 330, 332  
Bcr-Abl, 177, 221–222, 221*b*, 221*f*  
BDNF (brain-derived neurotrophic factor), 115*ne*, 116–117  
Beale, John, 353  
Beall, Robert (Bob), 235*nc*  
Beam Therapeutics, 342*b*  
Becker muscular dystrophy, 139*ni*  
Becton Dickinson, 149  
Bedson, Henry, 347  
Behrens, Kathy, 154  
Behring, 359, 359*ng*  
Belimumab (Benlysta), 32, 182  
Belldgrun, Arie, 303  
Benlysta (belimumab), 32, 182  
Bennett, Frank, 255  
Bepirovirsen, 257  
Berg, Paul, 4–6, 30, 36*b*, 39, 62, 343, 403, 453  
Bermuda Accords, 189*b*, 190  
Bernstein, Karen, 422*b*  
Bertozi, Carolyn R., 454  
Besponsa (inotuzumab), 90  
Best, Charles, 10*no*  
β-amyloid, 103–107  
β-globin genes, 11, 34, 35*nq*, 281, 285–287, 285*b*–286*b*, 315, 286*b*, 315, 335, 337, P124  
β-secretase, 104–105  
β-thalassaemia, 281, 285–287, 285*b*–286*b*, 315, 319–320, 330–334, 337

- Betaferon, 20  
Betaseron, 65  
Bethesda Research Laboratories (BRL), 24, 35*nq*, 404, 405*b*  
Betjeman, John, 29  
Beutler, Bruce, 97, 97*nb*, 452  
Bevacizumab (Avastin), 74  
Bexxar (tositumomab), 90  
Bezos, Jeff, 392  
BG Medicine, 368, 368*nq*  
BGI (Beijing Genomics), 170, 170*b*, 172  
Bigham, Michael, 259, 259*nh*  
Biktarvy, 412*b*  
Bill and Melinda Gates Foundation, 364, 370–372  
Bingham, Catherine (Kate), 361, 430  
*BioCentury*, 422, 422*b*  
Biogen, 8, 8*ni*, 11–13, 21, 85–86, 105–106, 132, 241, 241*no*, 243, 437  
Biologics licence applications (BLAs), 238, 437  
BioMarin, 238, 238*b*, 283–284  
Bionomics, 227, 242, 242*np*  
BioNTech, 370–372, 374–375, 379, 436  
Biotech space (in UK), 409–410, 410*nm*  
Biotechnology Innovation Organization (BIO), 423  
Biotechnology Investments Limited (BIL), 28, 32–33, 33*b*  
Biotechnology Value Fund (BVF), 432  
Bioverativ, 45, 93, 243–247, 280, 282–283, 319–321  
*BioWorld*, 422*b*  
Bird, Jeffrey (Jeff), 259, 259*ni*  
Birndorf, Howard, 76, 84, 123  
Bischofberger, Norbert, 259  
Bishop, Hans, 298*nj*, 305, 392, 393  
Bishop, Michael, 82, 88, 154, 258, 452  
Bispecific antibodies, 90–94, 310*b*  
Bitterman, Kevin, 331, 429  
Black Death, 357*nf*  
Blackburn, Elizabeth, 258, 452  
Blair, James (Jim), 54  
Blair, Tony, 191, 263  
BLAs (biologics licence applications), 238, 437  
Blech, David and Isaac, 80, 120–121  
Blinatumomab, 91  
Blindness, inherited, 278–279, 279*b*  
Blood clotting factors, 40–45  
bluebird bio, 287  
Bluestone, Jeffrey (Jeff), 84  
Blumberg, Baruch, 352, 451  
Board of Directors, 338, 338*nt*, 418–419  
Boch, Jens, 321–322  
Bock, Lawrence (Larry), 104  
Bock, Louis (Lou), 219  
Bodmer, Mark, 98–99  
Boehringer Ingelheim, 16, 38, 143, 254, 412*b*  
Boehringer Mannheim, 46  
Boger, Joshua (Josh), 123, 235  
Bok, Derek, 34–35, 35*np*  
Bollag, Gideon, 124  
Bonderman, David, 388  
Bone morphogenetic protein (BMP), 41, 204  
Booth, Bruce, 429  
Boots-Celltech Diagnostics (BCD), 32  
Bortezomib (Velcade), 150  
Bosley, Katrine, 332  
Boss patent, 72  
Botstein, David, 136*b*  
Bourke, Fred, 214, 214*nc*  
Bowes, William, 53  
Bowes melanoma cell line, 39  
Boyer, Herbert (Herb), 4–5, 4*ne*, 8–9, 9*nj*, 11, 13, 316  
Bradley, Allan, 75, 142  
Brady, Roscoe, 236  
BRAF inhibitors, 206  
*BRCA1* gene, 152–153, 152*njj*  
Breast cancer, 87–89, 152–153, 397  
Brenner, Malcolm, 274, 301  
Brenner, Sydney, 7, 28, 30, 39*ny*, 40, 54, 59, 59*nn*, 168*b*, 173, 207*ng*, 217  
Brentjens, Renier, 305, 305*ns*  
Brentuximab vedotin (Adcetris), 90  
Brexucabtagene autoleucl (Tecartus), 304  
Breyanzi, 306  
Brin, Sergey, 157  
Bristol-Myers Squibb (BMS), 75, 80, 83–84, 86–87, 101–102, 149, 303, 409  
British & Commonwealth Shipping, 28, 32  
British biotechnology, 33*b*  
Broad Institute, 325–328, 331, 337, 339  
Brodalumab (Siliq), 109  
Bronx High School of Science, 116, 116*ng*  
Brown, Alex, 122  
Brown, Eugene, 36*b*  
Brown, Fred, 348  
Brown, Michael, 117, 452  
Brudnick, Richard, 246, 339  
Bruton's tyrosine kinase (BTK), 192, 192*noo*  
BTK inhibitor, 101, 433  
Buchanan, Sean, 216, P118  
Buckler, Alan, 142  
Burnham Institute, 246–247  
Burrill, Steven, 420  
Burroughs Wellcome, 40  
Buy side funds, 432–434  
Byers, Brook, 9*nk*, 54, 76, 84–85, 123–124, 420, 424  
**C**  
C4 Therapeutics, 398  
“Cabilly” patents, 72–73  
Cabozantinib (Cometriq), 206–207  
Cadus, 87*b*  
*Caenorhabditis elegans*, 181, 187, 201, 207–210, 262  
Calcitonin, 31  
Calcitonin gene-related peptide (CGRP), 31  
Calicheamicin, 89–90  
Calicivirus, 239  
California Institute of Technology (Caltech), 34  
Cambridge Antibody Technology (CAT), 32, 74–75, 97, 97*na*, 182  
Cambridge Discovery Chemistry, 151  
CAMPATH 1 (alemtuzumab), 71, 71*ne*, 71*nf*, 150, 238, 238*nj*  
Campbell, Simon, 218  
Canavan, Neil, 300  
Cancer, 84–86, 100, 102–103, 152–153, 195, 195*nuu*, 255, 355–356, 371–372, 388, 392–393, 395, 397–398  
Cancer diagnostics, 392–393  
Cancer Research Campaign (CRC) Labs, 22–23  
Canji, 62  
CanSino Biologics, 366  
Cape, Ron, 1, 8  
Capecchi, Mario, 75, 452  
Caplan, Arthur (Art), 187  
Capstan Therapeutics, 308*b*

- CAR (chimeric antigen receptor) T, 287, 295, 295*na*, 300–309, 302*b*, 302*f*, 302*no*, 305*ns*, 306*nv*, 307*nw*, 308*b*, 312, 329–330, 390, 391
- Caraway Therapeutics, 194, 194*ntt*
- Cardon, Lon, 144
- Carey, Norman, 29, 29*ne*
- Carfilzomib, 396
- Caribou Biosciences, 329–330, 333, 333*nr*, 334
- Carpenter, Robert (Bob), 35*nr*, 237
- Carragher, Neil, 410
- Carter, Bruce, 409*b*, P130
- Carter, Paul, 89
- Caruthers, Marvin (Marv), 17, 53, 53*na*, 56*nf*, 250
- Carvey, Bradley (Brad), 167, 167*nc*
- Casgevvy (exagamglogene autotemcel), 331
- Casirivimab/imdevimab, 376*b*, 376*nc*
- Catamaran Bio, 266*nq*, 311–312, 341
- Cavendish Laboratory, 286*b*, 286*nh*
- CCR5 gene, 318–319, 318*b*, 343
- CD3, 72, 301
- CD4/6 kinase inhibitors, 125
- CD19-directed CAR T, 301, 303–305, 305*ns*
- CD20, 85, 90, 304
- CD28 gene, 301, 305
- CD34, in gene therapy, 274, 278, 280–281, 286–287
- CD47, 261
- CD52, 71
- cDNA cloning, 3, 3*f*, 11–12, 30–31, 42, 43*f*, 46, 60, 180, 237
- cDNA sequencing, 173–174, 180
- CDR grafting, 73–74, 101, P16
- Ced9* gene, 209
- Celera, 147, 163–164, 166*b*, 183–192, 185*b*, 187, 187*nf*, 192
- Celgene, 102, 303, 305, 388, 412*b*, 425
- Cell Genesys, 295–300, 301, 303, 304–305, 309–312, 309*b*–310*b*, 311*b*, 390, 390*b*
- Cell therapy, 295–312, 302*b*, 302*f*, 302*no*, 305*ns*, 306*nv*, 307*nw*, 308*b*
- Collectis, 322*b*, 334
- Celltech, 8*ni*, 16*nx*, 16*ny*, 28–33, 28*nd*, 71, 72, 74, 99
- Cemiplimab (Libtayo), 92, 119
- Centocor, 16, 55, 77–79, 98, 435–436
- Cephalon, 127–128
- CEPI (Coalition for Epidemic Preparedness Initiative), 365, 372
- Cerami, Anthony (Tony), 97–98
- Ceredase, 237
- Ceregene, 318
- Cerevel Therapeutics, 128–129, 128*ny*
- Cerezyme, 237, 239
- Certolizumab pegol (Cimzia), 99
- Cervarix, 356
- Cetus, 1–2, 8, 20, 22–23, 24, 31, 32, 64, 385
- Cetuximab (Erbix), 86–87, 87*nv*, 434
- Chalfie, Martin, 453
- Chambon, Philippe, 218*ng*, 219
- Chandran, Siddharthan, 410
- Chang, David, 303
- CHARM Therapeutics, 229*b*
- Charon (river Styx boatman), 42*naa*, P14
- Charpentier, Emmanuelle, 324–328, 330–331, 403, 454
- Checkpoint inhibitors, 99–102, 102*nj*
- ChemGenex Pharmaceuticals, 127–128
- Chemgenics, 149
- Chemical synthesis of nucleic acids, 11, 11*nq*, 13–14
- Chester Beatty Research Institute, 296*b*, 296*nc*
- Chien, Kenneth (Ken), 367
- Chikungunya virus, 370
- Chimpanzee adenovirus vector, 365, 365*n*
- Chiron, 20, 23, 63–65, 353, 359–360
- Chiroscience, 33
- Choo, Yen, 317
- Christopoulos, Arthur (Art), 227
- Chronic granulomatous disease (CGD), 19
- Chronic lymphocytic leukaemia (CLL), 150, 238*nj*, 295
- Chronic myelogenous leukemia (CML), 128, 177, 221*b*
- Chugai, 46, 93, 107, 245
- Church, George, 325–326, 331, 395
- Chymosin, 30, 30*nh*, 30*ni*
- Cialis (tadalafil), 122
- Ciba-Geigy, 63, 252
- Cidofovir (Vistide), 259
- Ciliary neurotrophic factor (CNTF), 115*ne*
- Ciltacabtagene autoleucl (CARVYKTI), 307
- Cimzia (certolizumab), 99
- Circumsporozoite protein (CSP) malaria vaccines, 354, 354*b*
- City of Hope Hospital, 11–12, 72–73
- Clapton, Eric, 306*nv*
- Clark, Edward (Ed), 81
- Clark, Steven (Steve), 366*b*
- Clarke, John, 262
- Clarus, 241
- Cleveland, Don, 255
- Clinton, William (Bill), 191, 263
- Clinton–Blair statement, 191
- Cluster theory, 407
- Clustered regularly interspaced short palindromic repeats. *See* CRISPR-Cas9
- Cobimetinib, 206
- Codexis, 211*b*
- Codiak BioSciences, 373
- Cogen Immune Medicines, 310
- Cohen, Charlie, 204, P117
- Cohen, Daniel, 147
- Cohen, Joshua (Josh), 130
- Cohen, Seymour, 21
- Cohen, Stanley (Stan), 4–5, 4*ne*, 22, 40
- Cold agglutinin disease, 245
- Cold Spring Harbor, 12, 38, 40
- Cole, Douglas (Doug), 132, 367, 427
- Colella, Samuel (Sam), 124, 218
- Coles, Tony, 129
- Collaborative Research, 24, 136*b*
- Collins, Cynthia, 332
- Collins, Francis, 137–138, 184, 189, 191, 202
- Columbia University, 35*nq*, 116, 193, 211*nk*, 213, 216, 243, 433
- Comirnaty, 375
- Committee on Recombinant DNA, 5
- Compaq, 186, 186*nee*, 221
- Complement system, 245–246, 245*b*

- Complete Genomics, 169–170, 172  
Conatus, 209  
ConfometRx, 226  
Convergence Pharmaceuticals, 240–241, 360  
Cooke, Joseph (Joe), 123  
Cor Therapeutics, 151  
Corixa, 90  
CoronaVac, 363  
Coronaviruses, 362–380  
Corticotropin-releasing factor (CRF), 126  
Coulter Pharmaceutical, 90  
Court of Appeals for the Federal Circuit (CAFC), 47  
COVID-19. *See* SARS-CoV-2  
Covishield, 375  
Cowen, Max, 205  
Cowpox (vaccinia), 347, 348*na*  
Cox, David, 153  
Cox, John, 243–244, 243*nr*, 246, 310  
Crandell, Keith, 427  
Crea, Roberto, 11, 204  
Creative BioMolecules, 204  
Creutzfeldt–Jakob disease, 15, 435  
Crews, Craig, 396–397  
Crick, Sir Francis, 2, 22, 173, 352, 451  
CRISPR-Cas9, 322–335, 325*f*, 323*nf*, 326*ng*, 326*nh*, 336, 341*b*  
CRISPR Therapeutics, 316, 321, 328, 330–331, 332, 334, 335  
Crizanlizumab (Adakveo), 287, 288*b*  
Crohn's disease, 98, 254  
Crooke, Stan, 250–254, 250*nb*, 263, 417  
Cryo-electron microscopy (cryo-EM), 226  
CSL Behring, 182  
CSL Seqirus, 356, 359  
CTL4, 84  
CuraGen, 166–167, 203  
CureVac, 372, 372*nu*  
Cystic fibrosis (CF), 65, 233, 411, 413*b*, 432*ncc*, 436  
Cystic Fibrosis Foundation (CFF), 220, 234–235, 235*nc*  
Cystic fibrosis transmembrane receptor (CFTR), 137–138, 137*nc*, 210, 220, 234–235, 235*nd*  
Cytidine deaminase, 325*f*, 336  
Cytokine release syndrome (CRS), 305–307, 306*nu*  
“Cytokine trap,” 117, 118*b*  
Cytokines, 58, 60, 62, 64  
Cytomegalovirus (CMV), 253, 259, 301  
**D**  
Daiichi Sankyo, 304  
D'Amico, Kevin, 219, P121  
“Dane” particles, 352  
*Danio rerio*, 201  
Danon disease, 291  
Darigabat, 129  
Darman, Richard (Dick), 145  
Darzalex, 413*b*  
Dasatinib, 222  
David, Nathaniel, 218  
Davie, Earl, 42, 60, 409*b*  
Davies, Kevin, 183, 343  
Davis, Mark, 300*nn*  
Davis, Ronald (Ron), 136*b*  
De Rubertis, Francesco, 430  
Decibel, 120  
Decipher, 76  
DeCODE Genetics, 154–156, 156*pp*–156*nqq*  
DeepMind AlphaFold, 228–229  
Deerfield, 434  
Del Mar races, 216–217, 217*ne*  
Delandistrogene moxeparvovec-rolk (Elevidys), 291  
DeLisi, Charles, 183  
Deltagen, 422  
Delyani, John, 305*nt*  
Dementia Discovery Fund (DDF), 108, 431  
Denali Therapeutics, 131–132, 132*nff*–132*nhh*  
Dendreon, 295*nb*, 297–300, 297*nh*, 298*nj*, 299*nk*–299*nm*  
Dengue fever, 349–350, 350*b*  
Dengvaxia, 350, 350*b*  
Denner, Alexander (Alex), 434, 434*nff*–434*ngg*  
Department of Energy (DOE), 183, 190  
Department of Trade and Industry (DTI), 28  
Dervan, Peter, 258  
Deshais, Ray, 396  
DeSilva, Ashanthi, 276  
Detrick, Fort, 12, 12*ns*  
Diabetic macular edema (DME), 94  
DiaDexus, 175*nm*  
Diamond Shamrock Ventures, 59  
Dicerna Pharmaceuticals, 266  
Dietz, Ryan, 367  
DiFabio, Andrea, 246  
Diffuse large B-cell lymphoma (DLBCL), 303–305, 307, 398  
Dihydrofolate reductase (DHFR) amplification system, 16, 22, 30  
Dimension Therapeutics, 283  
Direct-to-consumer (DTC) advertising, 412*nn*  
DiscovEHR partnership, 195–196  
Dix, Clive, 360–361, 360*nh*  
DNA microarray, 145*b*  
DNA sequencing, 163–197, 165*b*, 166*b*, 167*b*, 168*b*, 169*ng*, 170*b*, 171*nj*, 172*nk*, 173*b*, 177*no*, 185*b*, 185*ndd*, 186*b*, 189*b*, 190*njj*  
DNA sequencing machines, Applied Biosystems (ABI) PRISM, 166*b*, 185–186, 185*ncc*  
DNA shuffling, 210, 211*b*, 210  
DNA synthesizers, 11*nq*, 250  
DNA virus vectors for vaccines, 365–366  
DNAX, 62  
Dodgson, Mark, 28, 32  
Doherty, Peter C., 296*nd*, 452  
Domain Associates, 59  
Domain Partners, 54  
Domantis, 74  
Donanemab, 107  
Donnelly, Peter, 196*b*  
Dooney, Peter, 214*nc*  
Doudna, Jennifer, 325–329, 329*nm*, 331–332, 343, 394, 403, 454  
Down's syndrome, 190  
Dracopoli, Nicholas (Nic), 142  
Drakeman, Donald, 102  
Drayna, Dennis, 153  
Drayson, Paul, 360, 360*b*  
Drayson Racing Technology, 360*b*  
Drews, Jürgen, 201  
DRI Capital, 101  
Drmanac, Radoje (Rade), 169  
*Drosophila melanogaster*, 181, 188, 201, 202, 203–204, 202*na*  
Dubochet, Jacques, 226, 454  
Duchenne muscular dystrophy (DMD), 138–139, 268, 290–291, 139*ng*  
Duffield, Jeremy, 339

- Dulbecco, Renato, *4nd*, 183, 451  
Duncan, David Ewing, 222, 222*nm*, 420  
Dupilumab (Dupixent), 75, 118, 119*nj*, 413*b*  
Duyk, Geoffrey (Geoff), 206  
Duzan, Stephen (Steve), 59  
Dynavax, 364  
Dyno Therapeutics, 292  
Dystrophin, 139, 139*ni*, 290–291
- E**  
E3 ubiquitin ligase, 396*b*  
Eaton, Mike, 29  
Ebola virus, vaccine for, 364  
Eculizumab (Soliris), 245*b*  
Edelman, Gerald (Gerry), 67, 451  
Edelman, Joseph (Joe), 433  
Editas Medicine, 305, 331–332, 334  
Efanesoctocog alfa, 45, 244–245, 245*nt*  
Efstratiadis, Argiris, 11  
Eisai, 106–107, 106*no*, 253, 355, 431  
Eladocagene exuparovec (Upstaza), 289  
Elagolix (Orilissa), 127  
Elan, 105  
Elevidys (delandistrogene moxeparovec-rokl), 291  
Eli Lilly, 10, 13–15, 77, 79, 87, 93*b*, 107, 109 122–123, 126, 134, 148–149, 223, 293, 340, 376*b*, 408*nk*, 433  
Ellington, Andrew (Andy), 267  
ELOCTATE (Factor VIII-Fc), 45, 93, 244, 425  
Emicizumab (Hemlibra), 93, 93*nx*, 245  
Emraclidine, 129  
Emtage, Spencer, 29–31, 72, 216  
Emtricitabine (Emtriva), 260  
Enara Therapeutics, 410  
Enbrel, 55, 62–63, 98  
Enders, John, 351, 451  
Endotoxin contamination, 17, 17*ncc*  
Engelman, Edgar (Ed), 297  
Engerix-B, 353  
Enjaymo, 246*nu*  
Ensemble Discovery Corp, 336  
Enzyme families, 121–122  
Enzyme replacement therapy, 236–239, 371  
EpCAM (17-1A), 79  
Epidermal growth factor (EGF), 86, 117, 297  
Epidermal growth factor receptor (EGFR), 75, 86, 87*nv*, 92  
Epilepsy, 127, 129, 241–243  
EPOGEN, 55  
Epstein–Barr virus (EBV), 301  
Erbitux (cetuximab), 86–87, 87*nv*, 434  
Erikson, Deborah, 220  
Erlotinib (Tarceva), 260  
eRNA (endless RNA), 391–392  
Erythropoietin (EPO), 16, 31, 45–47, 47*ngg*, 47*nhh*, 435, 54–55, 406, 411  
Eshhar, Zelig, 301  
Evans, John, 336, 339  
Evans, Martin, 75, 452  
Evans, Ron, 123  
Evans-Freke, Stephen, 16, 125*nr*  
Evnin, Anthony (Tony), 35, 205, 258, 425  
Evolocumab (Repatha), 119  
Evrysdi (risdiplam), 257  
Evusheld (tixagevimab/cilgavimab), 376*b*  
Ex vivo gene therapy, 274, 280–281, 286  
Exagamglogene autotemcel (Casgevy), 331  
Exelixis, P117, 201–207  
Exenatide (Byetta), 123  
Exendin-4, 123  
Exon skipping, 139*ni*, 290  
Expansion Therapeutics, 269*b*  
Expressed sequence tags (ESTs), 173–183, 177*no*, 190*njj*  
Expression cloning, 60, 62  
Eye disorders 93*b*, 94, 267, 253, 259, 278–280, 279*b*, 332  
Eylea, 118*b*, 412*b*
- F**  
Fabrazyme, 237, 239  
Fabry's disease, 237  
Factor IX, 41, 45, 93, 182, 244, 282–283  
Factor VIII, 40–45, 93, 211, 282–284  
Factor X, 93, 412  
Fairtlough, Gerard, 29  
Familial hypercholesterolaemia, 118–119, 340  
Fanconi anaemia, 291  
Farber, Dana, 221  
Faricimab (Vabysmo), 94  
Farley, Peter, 1, 8  
Fate Therapeutics, 220*ni*, 311*b*  
Fax machine, 422*b*, 422*ny*  
Fearon, Douglas (Doug), 124  
Feldbaum, Carl, 423  
Feldmann, Marc, 98  
Felgner, Philip (Phil), 277  
Ferguson, Ken, 121–122  
Fidanacogene elaparovec, 283  
Fidelity, 434  
Fiers, Walter, 164  
Filgrastim, 55  
Finer, Jeffrey (Jeff), 226  
Fire, Andrew (Andy), 210, 262, 403, 452  
Fisherman, Jason, 205  
Fishman, Mark, 102, 333  
Fitusiran, 265  
Flagship Pioneering, 385, 389–391, 426, 427–428  
Flavell, Richard, 203–204  
Flavivirus, 349, 349*b*  
Flores, David, 422*b*  
Flow Laboratories, 77  
Fluad, 359  
Flubok, 359  
Flucelvac Quadrivalent, 359  
FluMist, 361–362  
Fluzone, 359  
Fodor, Stephen (Steve), 145*b*  
Foetal haemoglobin, 285, 285*ng*, 286*b*, 315*na*, 337  
Fok1, 316, 317*b*  
Fomivirsen, 253  
Fondation Santé, 421–422  
Food and Drug Administration (FDA), 78–79, 86, 89, 106, 107, 131, 241, 245, 421, 423  
Foot and mouth disease virus (FMDV), 27, 27*nc*, 274, 352  
Forma, 288*b*, 288*nk*  
Formela, Jean-François, 205, 215, 218*ng*, 332, 429, P117  
Forrest, Michael, 154  
Forty-Seven Inc., 261*m*, 261*nm*  
Forward Ventures, 76  
Foundation Medicine, 194–195, 195*nuu*  
454 Life Sciences, 166–167, 167*b*, 203  
Frank, Frederick (Fred), 222*nm*, 420  
Frank, Joachim, 226, 454  
Fraser, Claire, 187, 190, 193*npp*  
Frazer, Ian, 355  
Fred Hutchinson Cancer Center (The Hutch), 57–59, 57*nh*, 80  
Freeline Therapeutics, 283



- Friedman, Jeffrey (Jeff), 147–148  
Friedman, Paul, 177  
Friedmann, Theodore (Ted), 273  
Friedreich's ataxia, 289  
Friend, Steve, 263  
Fritsch, Edward (Ed), 34, 36*b*, 42, 46, 285  
Fritz, Larry, 104  
Froehler, Brian, 258  
Froguel, Philippe, 143  
Frontotemporal lobe dementia (FTD), 108–109  
Fugu genome, 197  
Fujirebio Inc., 79  
Fuller, Forrest, 11  
Functional genomics, 201–211  
Furth, Mark, 116  
Fusogen technologies, 390*b*
- G**  
G protein-coupled receptor (GPCR), 87*b*, 114–115, 118, 224–228, 225*np*, 234  
Gaasterland, Theresa (Terry), 217  
Gabitril (tiagabine), 127  
Gabrieli, Christopher (Chris), 250  
Gage, Patrick, 48  
Gajdusek, D. Carleton, 451  
Galakatos, Nicholas (Nick), 241  
Galapagos, 420  
Gallatin, Michael (Mike), 122  
Galleri test, 392  
Gallo, Robert (Bob), 82  
GammaDelta Therapeutics, 309*b*–310*b*  
 $\gamma\delta$  T cells, 309, 309*b*–310*b*  
 $\gamma$ -globin, 315, 315*na*, 332, 337  
 $\gamma$ -retrovirus vectors, 275, 278, 280  
 $\gamma$ -secretase, 104  
Gandeeva Therapeutics, 227  
Gantenerumab, 107  
Gardasil, 356  
Garraway, Levi, 194  
Gates, Bill, 121, 121*nm*, 332, 392  
Gateway cloning system, 405*b*  
Gaucher's disease, 236–237, 236*nf*  
Gaudelli, Nicole, 337  
Geisinger Health, 118, 195–196  
Gelsinger, Jesse, 277  
Gemtuzumab ozogamicin (Mylotarg), 89  
Gendaq, 317  
Gene chips, 145*b*  
Gene editing, 315–344, 325*f*, 342*b*  
Gene editing companies, 316–343, 321*nc*, 322*b*, 325*f*, 326*ng*, 340*b*–341*b*  
Gene therapy, 273–293, 273*na*, 275*b*–276*b*, 278*nd*, 279*b*, 285*b*–286*b*, 288*ni*, 279*b*, 308*b*  
Gene writing, 341–343, 342*b*  
GeneFormatics, 218  
Genentech 1, 8–9, 16–17, 17*naa*, 22, 27, 27*nc*, 31, 41–44, 43*bbb*, 206, 396–397  
Genentech *versus* Wellcome  $\tau$ -PA patent case, 38–40  
Genentech (IPO), 1–2, 1*na*, 10–13, 15–16, 18–20, 24, 28, 32, 72–74, 78, 91, 94, 385, 411, 435, Pl2  
Generate Biomedicines, 227  
Generation Bio, 292  
Genetic Manipulation Advisory Group (GMAG), 7  
Genetic Systems, 80–84  
Genetic Therapy Inc. (GTI), 276  
Genetics Institute (GI), 9, 22, 31, 33–40, 36*b*, 37*nv*, 38*nx*, 41–49, 43*bbb*, 49, 415, 435  
Genetix, 286–287, 286*ni*  
Genex, 9–10, 10*nn*, 24  
Genome Analyzer, 168–169  
Genome Therapeutics, 136*b*  
Genome-wide association studies (GWAS), 145, 145*b*, 176  
Genomic cloning, 42, 43*f*, 46, 46*nf*  
Genomics, 132–133, 201–211, 213–230  
Genomics companies, 139–158, 157*b*  
Genomics England, 196, 196*b*  
Genoptix, 76  
Genos, 146–147, 147*naa*, Pl10  
GenPharm, 75, 210  
GenProbe, 65  
Genta, 251  
Genzyme, 16, 35*nr*, 236–240, 239*nk*–239*nl*, 289, 436, Pl22  
Georgetown University, 355–356  
Gerber, William (Bill), 124*nq*  
Gerngross, Tillman, 108  
Gething, Mary-Jane, 40  
Gibbs, Richard, 189  
GIBCO (Grand Island Biological Company), 405*b*  
Gilbert, Sarah, 365  
Gilbert, Walter (Wally), 7–8, 11, 19, 34, 46, 152, 164, 130*naa*, 403, 453  
Gilead Sciences, 57, 205, 242, 255, 257–261, 267, 303, 387, 411, 412*b*, 420, Pl23  
Gill, Simba, 211*b*, 427  
Gilliland, Gary, 221  
Gillis, Steven (Steve), 57–60, 58*ni*, 90, 98  
Gilman, Alfred (Al), 115, 117, 452  
Gilman, Michael, 269*b*  
Givosiran (Givlaari), 264  
Glaser, Donald, 1, 8  
Glasgow University, 31  
Glass, William, 143  
Glavin, James (Jim), 82  
Glaxo Genetics Initiative, 135, 137  
Glaxo Group Research (GGR), 113–115  
Glaxo Institute of Molecular Biology (GIMB), 21, 21*nee*, 117  
GlaxoSmithKline (GSK), 116–117, 120, 122, 126, 141, 141*nn*, 157–158, 182, 233, 250, 257, 259–260, 277, 280–281, 391, 354–356, 360, 365*b*, 372, 372*nu*, 394*b*, 413, Pl23  
Glick, Leslie, 9  
Global Blood Therapeutics (GBT), 288*b*  
Glucagon-like peptide-1 (GLP-1), 123, 225, 392  
Glucocerebrosidase (GCase), 132, 236–237  
Glucose 6 phosphatase, 338  
Glutamine synthetase amplification system, 30–31  
Glycogen storage disease, 338  
Glycolate oxidase, 264  
Goeddel, David (Dave), 18–19, 56, 91, 125*nr*, 147  
Gold, Larry, 56–57, 267, 268, 268*nr*  
Gold, Mitchell (Mitch), 298*nj*  
Goldstein, David, 193–194, 241–243, 343–344  
Goldstein, Joseph (Joe), 117, 452  
Goldwasser, Eugene, 45–46  
Golimumab (Symponi), 98  
Gonadotropin-releasing hormone (GnRH) antagonist, 127

- Goodfellow, Peter, 135, 176  
Goodman, Corey, 203, 204*nb*, 205, 205*nd*  
Goodman, Howard, 11–13, 352  
Gore, Al, 420, 423  
Gorman, Kevin, 126  
Gossamer Bio, 228  
Gottesdiener, Keith, 339  
GRAIL, 392–393  
Grais, Linda, 213–217, P118, P121  
Granulocyte colony-stimulating factor (G-CSF), 37, 54–55, 55*nd*, 61, 61*nq*  
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 61, 296, 296*b*, 299  
Gratton, David, 32  
Gray, Patrick (Pat), 19, 98, 352  
Greek Biotech meeting, 421–422, P130  
Green, Phil, 186  
Greenaway, Peter, 12  
Greenberg, Phil, 301, 305  
Greene, Barry, 263  
Greene, Howard (Ted), 76, 122  
Greenwood, James (Jim), 423  
Gregory, Dan, 35  
Gregory, Philip, 318  
Greider, Carol W., 452  
Groom, John, 104  
Growth hormone, 13–15, 435  
Guidelines for recombinant DNA research, 6–7  
Gurdon, John, 366*nm*, 452  
Gusella, James (Jim), 139
- H**  
Haemagglutinin (H or HA), 357–358  
Haemoglobin, 285–286, 285*ng*, 286*b*, 315*na*, 337  
*Haemophilus influenzae*, genome sequencing of, 180, 185*ndd*  
Haemophilia A, 40, 45, 245, 282–285, 320  
Haemophilia B, 41, 182, 282–285  
Hale, David, 76  
Hall, Benjamin (Ben), 60, 353, 409*b*  
Hall, Jeff, 152  
Hall, Stephen, 11*np*, 12, P11  
Hambrecht, Bill, 1*na*  
Hambrecht & Quist, 421, 421*nw*–421*nx*  
Hanahan, Douglas (Doug), 124  
Harbour BioMed, 92  
Harr, Steven (Steve), 390  
Harris, Bob, 12  
Harrison, Seth, 213, 215  
Hartley, Jim, 405*b*  
Hartwell, Leland, 189*b*, 452  
Harvard Management Group (HMG), 34, 34*nn*  
Harvard University, 7, 11, 34–35, 34*no*  
Harvoni, 260  
Haseltine, William (Bill), 178–179, 178*nq*, 181, 297  
Hassan, Fred, 48–49  
Haurwitz, Rachel, 329, 333  
Hayday, Adrian, 309*b*  
Hayman, Gale, 178  
HDR (homology-directed repair), 335  
He, Molly, 173*b*  
HealthCare Ventures (HCV), 177, 179, 204, 298  
Healy, Bernadine, 184  
Helgerson, Scott, 167  
Hellström, Ingegerd and Karl-Erik, 82  
Hemgenix, 283–284  
Hemlibra (emicizumab), 93, 93*nx*, 245  
Henderson, Richard, 225, 226, 454  
Hendrickson, Wayne, 213–217  
Henney, Chris, 57–60, 57*zh*, 58*ni*, 80, 83–84, 120–121, 218*ng*, 223, 297–298, 298*nj*, P130  
Hentschel, Chris, 101*ng*  
Hepatic porphyria, 264  
Hepatitis B virus (HBV), 257, 352–354, 354*b*  
Hepatitis C virus (HCV), 64, 260–261, 411  
Hepsera (adefovir), 260  
Heptares Therapeutics, 225, 225*np*  
HER2 (human epidermal growth factor receptor 2), 88  
Herceptin, 87–89  
Herd immunity, 377  
Hereditary angioedema, 334  
Hereditary persistence of foetal haemoglobin (HFPFH), 315*na*, 337  
Heritable human genome engineering (HHGE), 344  
Herodotus, 438  
Herpes simplex virus (HSV), 355  
Herpesvirus thymidine kinase (*HSV-TK*) gene, 276  
Hewick, Rod, 36*b*, 42, 46  
Hexagen, 176, 176*zn*  
Hexner, Thomas (Tom), 35  
Heyman, Richard, 427  
Hicks, James (Jim), 122  
Higgins, Arthur, P130  
High, Katherine (Kathy), 279  
Hill, Adrian, 365  
Hilleman, Maurice, 353  
Hirschmann, Ralph, 258  
Hirsh, David, 56  
*HLA-B7* gene, 277  
HLAs (human leukocyte antigens), 83, 309  
HMG (Harvard Management Group), 34, 34*nn*  
Hobden, Adrian, 153  
Hockmeyer, Wayne, 362  
Hodgkin, Dorothy, 10, 453  
Hoerr, Ingmar, 372  
Hoffmann, Jules A., 452  
Hoffmann-La Roche deCODE deal, 155  
Genetech and, 1*nb*, 17, 18  
Hofschneider, Peter, 352  
Hogness, David, 202  
Holley, Robert, 164, 451  
Holmes, Elizabeth, 208*ni*  
Holmes, Michael, 318, 342  
Holtzman, Steve, 148, 148*ngg*, 425  
Honig, Barry, 213–217  
Honjo, Tasuku, 403, 453  
Hood, Leroy (Lee), 36*b*, 53, 165, 405*b*  
Hopp, Dietmar, 372  
Horizon Therapeutics, 56  
Horowitz, Bradley, 390  
Horvath, Philippe, 324  
Horvath, Steve, 394  
Horvitz, H. Robert (Bob), 207, 207*ng*, 209, 452  
Houghton, Michael, 64, 64*nv*, 453  
Housman, David, 139, 142  
Houston, John, 117, 397  
Howard Hughes Foundation, 190, 205  
Howley, Peter, 124  
HSV (herpes simplex virus), 355  
*HSV-TK* gene, 276  
Huber, Christoph, 370  
Huber, Reid, 177  
Hudson, Leslie, 115, 120, 205  
Hudson-Alpha Institute for Biotechnology, 22, P116  
Humalog, 13  
Human epidermal growth factor receptor 2 (HER2), 88  
Human genome editing, 343–344, 343*nw*



- Human Genome Project (HGP), 163–164, 183–186, 188–192, 189*b*
- Human Genome Sciences (HGS), 178–183
- Human growth hormone (hGH), 13–15, 31
- Human immunodeficiency virus (HIV), 41, 83, 213, 260, 275, 303, 318–319, 318*b*, 343, 412*b*
- Human Longevity, 193, 193*nqq*
- Human papillomavirus (HPV), 254, 311, 355–356
- Humanising antibodies, 73–75, 73*b*
- Humatrope, 15
- HumGen (mythical company), 343–344
- Humira (adalimumab), 32, 63, 73–74, 97, 99, 411*b*, 413, 413*b*
- Humulin, 13
- Hunkapiller, Michael, 165, 405*b*
- Hunt, Tim, 189*b*, 452
- Hunter, Tony, 425
- Hunter syndrome, 320
- Huntington's disease (HD), 132*n*hh, 139, 282
- Hybrid selection, 18, 18*b*
- Hybridoma, 69–70, 69*b*, 72, 81
- Hybridon, 249, 263
- Hybritech, 31, 76–77, 76*nj*, 77*nl*
- Hydroxyurea, 287
- Hypercholesterolemia, 255, 265
- Hyperloxiuria, 264
- Hypertrophic cardiomyopathy, 291
- I**
- Iaronidase (Aldurazyme), 238, 238*b*
- IASO Bio, 390
- Ibrance (palbociclib), 125
- Imbrutinib (Imbruvica), 101, 192, 412*b*, 433
- Icahn, Carl, 87*b*, 393, 434
- Iceland, 154–155
- Icos, 57*nh*, 84, 120–122
- ICRF (Imperial Cancer Research Fund), 21–22, 22*b*
- Idec, 76, 84–86
- Idelvion, 182
- Idun Pharmaceuticals, 209
- Iduronate-2-sulfatase (IDS), 320
- Ilex Oncology, 238
- Illumina, 168–169, 169*ng*, 171*nj*, 172–173, 172*nk*, 392
- Imatinib (Gleevec), 221*b*, 222
- Imbruvica (ibrutinib), 102, 192, 412*b*, 433
- ImClone Systems, 86–87, 87*b*, 408*nk*
- ImmTAC platform, 92
- Immune effector cell-associated neurotoxicity syndrome (ICANS), 307
- Immunes, 37, 55, 57–63, 60*no*, 98
- Immunocore, 92, 93*b*
- Imperial Cancer Research Fund (ICRF), 21–22, 22*b*
- Imperial College, 30
- Imvamune, 348*na*
- Imvanex, 348*na*
- Inclisiran (Leqvio), 265
- Incubator concept, 407–408
- Incyte Genomics, 174–177, 175*b*, 190*nj*
- Indiplon, 126
- Induced pluripotent stem cells (iPSCs), 311, 366, 366*nm*
- Industrial Biotechnology Association (IBA), 423
- Inflation Reduction Act (2022), 411
- Infliximab (Remicade), 55, 79, 97–99, 98, 98*nc*, 436
- Influenza vaccines, 259, 356–362, 356*nd*–356*ne*, 357*b*, 357*nf*, 364, 369–370
- Ingram, Vernon, 286*b*
- Ingrezza (valbenazine), 127
- Initial public offering (IPO), 1–2, 1*na*, 8, 15–16, 20, 21, 28, 32, 38, 38*nx*, 54, 56, 57, 60–61, 77, 80–81, 109*b*, 116, 130, 132*nff*, 145–147, 149, 171, 172, 174, 180, 185*b*, 192, 192*n*nn, 206, 211, 223, 228, 229, 229*b*, 236–237, 242, 253–254, 253*nf*, 261*nm*, 263–264, 280, 281, 288*nk*, 292, 307, 309, 316–317, 330, 330*no*, 331, 332, 336, 339, 340, 368, 370, 371, 372, 385, 386–387, 390, 391, 394*b*, 395, 397, 398, 401, 404*b*, 407, Pl2, Pl11, Pl26
- Innovent, 390
- Inotuzumab (Besponsa), 90
- Inpharmatica Ltd., 218
- Insider trading, 86
- Insitro, 229
- Insulin, 10–13
- Insulin gene, cloning of, 11–13
- Integrated Genetics (IG), 35*nr*, 40, 237, 239
- Intellectual property (IP), 38, 44, 62, 184, 191, 326–327, 377, 379. See also Patent
- Intellia Therapeutics, 120, 332–335
- Interferon, 17–21
- Interferon- $\gamma$ , 16
- Interleukin-1 (IL-1), 55–56, 61–62, 98, 117, 118*b*
- Interleukin-2 (IL-2), 23, 64, 301
- Interleukin-4 (IL-4), 118
- Interleukin-23a (IL-23a), 411*b*
- InterMune, 19, 411
- Invisible Frontiers* (Hall), 11*np*, 12, Pl1
- Invitrogen, 176, 404*b*–405*b*
- Invitron Corporation, 174
- Invivyd, 376*b*
- Ion channels, 234
- Ion Torrent, 170
- Ionis, 250–257, 263
- Iovance, 65
- Ipilimumab (Yervoy), 102
- Isaacs, Alick, 17
- Isaacson, Walter, 343
- Isaly, Samuel, 432
- Ishino, Yoshizumi, 323
- Ishizaka, Kimishige, 58*ni*
- Isis. See Ionis
- Itakura, Keiichi, 11
- Ixekizumab (Taltz), 109
- J**
- J. Craig Venter Institute (JCVI), 193
- Jacob, François, 173
- Jacob, Robin, 39, 64*nw*
- Jacobs, Joe, 406, 407*b*
- Jaffe, Elizabeth, 295
- Jakimo, Alan, 203
- Janssen, 92, 98, 126
- Janus Capital Group, 434
- Janus kinase (JAK) inhibitors, 177, 412*b*
- JC virus, 20–21
- Jenner, Edward, 347
- Jenner, Kris, 434
- Jenner Institute, 354*b*, 365
- Jerne, Niels, 69, 69*b*, 403, 451
- Jesty, Benjamin, 347
- J.H. Whitney, 384
- Jhoti, Harren, 217
- Jiankui, He, 343, 343*nw*
- Jinek, Martin, 329

## 470 Index

- Johnson, Carl, 207–208, 208*nh*, 210  
Johnson & Johnson (J&J), 31, 55, 46, 79, 98, 307, 366, 375, 412*b*, 413*b*. *See also* Janssen  
Johnston, Pitch, 54  
Johnston, Robert (Bob), 9  
Joint Genome Institute, 189, 191  
Jolie, Angelina, 152*njj*  
Joung, Keith, 331, 336  
J.P. Morgan investment conference, 421  
Judson, Horace, 2  
June, Carl, 301, 303, 305, 308*b*  
Juno Therapeutics, 304–305, 332, 387–388
- K**  
K-*ras*, 23  
Kabi Vitrum, 13–14  
Kahvejian, Avak, 391  
Kakkis, Emil, 238*b*  
Kalydeco, 235  
Kamei, Nancy, 124–125  
Kamen, Robert (Bob), 36*b*  
Karikó, Katalin, 367, 367*nm*–367*no*, 371, 371*nt*, 403, 453  
Karuna Therapeutics, 129–130  
Kaufman, Randy, 31, 36*b*  
Kay, Bob, 40  
Kazam, Joshua, 303  
Kendrew, John, 453  
Kerr, Doug, 292, 292*nn*  
Kevzara (sarilumab), 118, 119*nj*  
Keytruda (pembrolizumab), 70, 99–100, 102–103, 330, 412*b*, 413  
Khepri, 146*ny*  
Khorana, Har Gobind, 11*nq*, 12, 23*nhh*, 36*b*, 164*nc*, 451  
Kim, Jin-Soo, 326  
Kim, Peter, 100  
Kimmtrak (tebentafusp), 92, 93*b*  
Kinase inhibitors, 124–125, 192, 192*noo*, 206–207  
Kineret, 55  
King, Mary Claire, 152  
King, Rachel, 423  
Kinsella, Kevin, 122*no*, 124, 126, 148, 154–155, 205*nd*, 208, 210, 233, 421*nx*, P114  
Kirin Company, 46, 298  
Kite Pharma, 261, 303–304, 309, 387  
Klausner, Richard (Rick), 391, 393  
Klee, Justin, 130  
Kleid, Dennis, 27*na*  
Kleiner, Eugene (Gene), 424  
Kleiner, Perkins, Caufield & Byers (KP), 9, 9*nk*, 84, 384, 420, 424  
Klenerman, David, 168  
Klug, Aaron, 316–317, 316*nb*, 453  
Knight, Stephen, 132  
Knoll AG, 97  
Knopf, John, 36*b*, 41–42  
Knowles, Jay, 216, 219  
Knowles, Jonathan, 21*nee*, 117, 155, 201  
Kobilka, Brian, 224, 224*b*, 226, 227*nq*, 454  
Koch, Kevin, 432  
Kogenate, 44  
Köhler, Georges, 68–70, 70*nb*, 89, 403, 451  
Kolchinsky, Peter, 433  
Komor, Alexis, 337  
Koonin, Eugene, 324  
Koppel, Adam, 432  
Koprowski, Hilary, 70, 77  
Korman, Alan, 102  
Korn, Laurence, 74  
Kornberg, Arthur, 62, 117, 451  
Kramlich, Richard (Dick), 59  
KRAS mutations, 87*nv*  
Kucherlapati, Raju, 147–148  
Kulkarni, Samarth, 330  
Kunkel, Louis (Lou), 138  
Kymab, 75  
Kymera Therapeutics, 397–398  
Kymriah (tisagenlecleucel), 305–306  
Kynamro (mipomersen), 255
- L**  
*Lactobacillus*, 324  
Laguna Biotech CEO Forum, 420–421  
Laidlaw, Patrick, 357*b*  
λ Charon 4 vectors, 42*naa*  
λ phage repressor gene, 34  
*LAMP2* gene, 291  
Lampert, Mark, 432  
Lander, Eric, 147, 153, 189–190, 327  
Langer, Robert (Bob), 367, 434*ngg*  
Langer, Susan, 434*ngg*  
Lanphier, Edward (Ed), 316, 319  
LaPorte, Kathy, 146  
Laronde, 391–392  
Larotrectinib, 433  
Larsen, Glenn, 36*b*, 36*nt*, 38  
Lathi, Vijay, 219  
Latozinemab, 109  
Lawn, Richard, 42, 42*naa*, 285  
Lazarus, Steven (Steve), 427  
Le Duc, Carrie, 143  
Le Mans, 360*b*, P125  
Leach, Martin, 167  
Leathers, David, 59  
Leber's congenital amaurosis (LCA), 278–280, 332  
Lecanemab (Leqembi), 106–107, 106*no*, 437  
Ledbetter, Jeffrey (Jeff), 83–84  
Lederberg, Joshua (Josh), 22, 217  
Lederle Laboratories, 355  
Ledoux, Bruce, 429*b*  
Lee, Aileen, 389  
Leeson, Nick, 32*nk*  
Lefkowitz, Robert (Bob), 224*b*, 226–227, 227*nq*, 454  
Legend Biotech, 307  
Lehrach, Hans, 139, 142  
Lemtrada, 71*ne*, 238*nj*  
Lengyel, Peter, 18  
Lentivirus vectors, 275, 278, 281, 287, 291, 295  
Leonard, John, 333  
Leptin, 148  
Lerner, Irwin, 146  
Leschly, Jan, 179, 287  
Leschly, Nick, 287, 306, 428  
Leukine, 61  
Leukocyte adhesion deficiency type I (LAD I), 291  
LeukoSite, Inc., 150, 367  
Levin, Jeremy, 102, 215*nd*  
Levin, Mark, 147–148, 150*mii*, 151, 204, 297, 426  
Levine, Arnie, 87*b*, 187  
Levine, Bruce, 308*b*  
Levinson, Arthur (Art), 88  
Lewin, Benjamin, 328*nl*  
Lewinsky, Monica, 190  
Lewis, Alan, 425  
Lewis, Michael, 127  
Lexicon Genetics, 176*b*  
Li, Haodong, 182  
Libmeldy, 281  
Libtayo (cemiplimab), 92, 119  
Lichter, Jay, 142, 142*nr*  
Life Technologies, 170, 405*b*  
LifeArc, 70, 101*nh*, 410  
LifeSeq database, 175*b*  
Ligand Pharmaceuticals, 76, 123–124  
Lima, Christopher (Chris), 213, 215, 217  
Limited Partners (LPs), 401, 401*na*  
Lindenmann, Jean, 17  
Lindsay, Ronald (Ron), 116, 149

- Linsley, Peter, 84  
Lipid nanoparticles (LNPs),  
263, 292, 333–334, 338,  
362, 368  
Lipoplexes, use in gene therapy,  
277  
Lipoprotein a (Lpa), 340  
Lipoprotein lipase (LPL)  
deficiency, 282  
5-lipoxygenase, 252  
Lisocabtagene maraleucel (lis-  
cel, Breyanzi), 305  
Liu, David, 331, 335–336, 338,  
341*b*  
Lodge at Torrey Pines, 141,  
141*no*  
Loftus, Peter, 367, 368*nq*  
Lohmer, Stefan, 150*nhh*  
Lonberg, Nils, 102  
Lone Pine Capital, 434  
Long COVID syndrome, 377*b*  
*The Long Good Friday* (film),  
23, 23*nff*  
Longboard Pharmaceuticals,  
227  
Lonza, 31, 71  
Low-density lipoproteins  
(LDLs), 119, 119*ni*, 265  
Lowy, Douglas (Doug), 356  
Loxo Oncology, 432–433  
LRRK2, 132, 132*nii*  
Lubrizol, 15  
Lumasiran, 264–265  
Lunsumio (mosunetuzumab-  
axgb), 91  
Lupus nephritis, 182  
Luxturna (voretigene  
neparvovec-rzyl), 279,  
279*ne*  
Lyell Immunopharma, 391,  
391*ng*  
Lying-In Maternity  
Hospital, 37  
Lymphocyte trafficking,  
227–228, 228*nr*  
Lynch syndrome, 103, 180  
Lynparza (Olaparib), 413  
Lynx Therapeutics, 168*b*  
Lyons, Gary, 126–127  
Lysosomal storage disease,  
236–238  
LYTACs, 398  
**M**  
Maassab, John, 361, 361*nj*  
Mach, Bernard, 8, 46  
Macleod, John James, 10, 10*no*,  
451  
MacQuitty, Jonathan, 261*nm*  
Macrae, Alexander (Sandy),  
319–320  
Macrophage colony-stimulating  
factor (M-CSF), 37  
Macugen, 267  
Mak, Tak, 300*nn*  
Makani, Julie, 321  
Makarova, Kira, 324  
Malaria vaccines, 286*b*, 354,  
354*b*  
Maniatis, Tom, 11, 29–30,  
34–36, 35*nq*, 42, 46, 285,  
Pl3  
Manteia, 168*b*  
Mantle cell lymphoma (MCL),  
304  
MAPKK (mitogen-activated  
kinase kinase) inhibitor,  
206  
Maraganore, John, 149, 262–  
266, 341*b*, 342*b*, 427  
Marcus, Joel, 123, 406–407  
Marr, Tom, 142  
Marraffini, Luciano, 326–327,  
327*nj*, 333  
Marshall, Chris, 22–23  
Marshall, Fiona, 225  
Martin, John, 259  
Massachusetts Institute of  
Technology (MIT), 5,  
7, 88  
Matteucci, Mark, 17, 258  
Matthews, Bill, 422, Pl30  
Maxam–Gilbert sequencing,  
164, 165*b*, Pl15  
Maxygen, 210–211, 211*b*  
McCance, Henry, 35  
McCarthy, Sean, 222  
McClintock, Barbara, 341, 451  
McConnell, Thomas (Tom), 145  
McCormick, Frank, 21–22, 22*b*,  
31, 64, 124–125, 153  
McCullagh, Keith, 33*b*  
McDevitt, Hugh, 60  
McDonough, Geoff, 292  
McGinnis, William (Bill), 210  
McHutchison, John, 243  
McKnight, Steven (Steve), 56,  
147  
McKusick, Victor, 187  
McQueen, Steve, 360*b*  
Medarex, 75, 101–102, 177  
Medeva, 33  
Medical Research Council  
(MRC), 28, 30, 68–71  
Medicare, 411, 413  
The Medicines Company, 265  
Medicix, 430  
MediGene, 93*b*  
MedImmune, 32, 72, 74, 355,  
361–362  
Megabios, 277  
MEK inhibitor, 206  
Melanoma, uveal, 93*b*  
Meldrum, Peter, 152  
Mello, Craig, 210, 262, 403, 452  
Melton, Doug, 258  
Memorial Sloan Kettering  
Cancer Center (MSKCC),  
55*nd*, 61, 80, 97, 146–147  
Mendelsohn, John, 86  
Mendelson, Alan, 54, 361*ni*  
Mendlein, John, 220*ni*, 311*b*,  
427  
Mercator Genetics, 153–154  
Merck, 49, 63, 100, 101, 102–  
103, 181, 194*ntt*, 263,  
353–354, 356, 369–370,  
412*b*, 413, 425, 435  
Merck KGaA, 86–87  
Merck Ventures, 431  
Merigan, Tom, 22  
Merrifield, Bruce, 11*nq*, 453  
MERS, 362, 366, 373  
Mertansine (Kadcyla), 89  
Messenger RNA (mRNA), 2, 3,  
3*b*. *See also* mRNA vaccines  
Metachromatic leukodystrophy,  
281  
Metagenomi, 340*b*–341*b*  
Metcalf, Donald (Don), 61,  
61*nq*  
Metalloproteinases, 30  
Meyerson, Matthew, 194  
MGI Technology, 170*b*, 172,  
172*nk*  
Microbiological Research  
Establishment (MRE),  
12–13, 12*ns*  
Micromet, 91  
Middleton, Fred, 115  
Midland Bank, 28  
Migraine, 233  
Mild cognitive impairment  
(MCI), 105–107  
Millennium BioTherapeutics, 149  
Millennium Pharmaceuticals,  
90, 147–151, 222–223,  
222*nn*, 262, 367, 436  
Millennium Predictive Medicine,  
149  
Miller, Andrew, 129  
Miller, Jacques, 296*b*, 296*nd*  
Milner, Yuri, 393  
Milstein, César, 30, 68–70, 68*b*,  
70*nb*, 70*nc*, 81, 89–90,  
403, 451, Pl5  
Mipomersen (Kynamro), 255

- Mirabelli, Christopher (Chris), 250
- Mirren, Helen, 23
- Misrock, Leslie, 204
- Mitapivat (Pyrukynd), 288*b*
- Mitchell, Graham, 296*b*
- Mitchison, Avrion, 81
- Mitogen-activated kinase kinase (MAPKK) inhibitor, 206
- Miyake, Takaji, 45–46
- MMR vaccine (measles, mumps, and rubella), 359
- Mobile genetic elements, 341–342, 341*nu*
- Modafinil (Provigil), 127
- Moderna, 340*b*, 362, 365*b*, 367–370, 370*ns*, 374–377, 379, 388, 388*nc*, 408, 408*ni*, 408*nj*, 413*b*, 436
- Mojica, Francisco, 323
- Molecular breeding, 210
- Molecular Cloning: A Laboratory Manual* (Maniatis), 29–30, 34, Pl3
- Molecular Dynamics, 166*b*
- Molecular Genetics, Inc. (MGI), 355
- MolMed, 280
- Moloney murine leukaemia virus, 275
- MOMA Therapeutics, 227
- Monaco, Anthony (Tony), 138, 142
- Monkeypox, 348, 348*na*
- Monoclonal antibodies (mAbs), 20, 28–29, 28*nd*, 31–32, 55, 63, 67–94, 69*b*, 69*f*, 71*nd*, 87*b*, 87*nv*, 97–110, 98*nc*, 102*nj*, 109*nt*, 228*nr*, 376*b*, 411*b*–412*b*, 412*nn*, 413, 413*b*, 425, 434, 436
- Monod, Jacques, 173
- Monsanto, 33*b*
- Montagnier, Luc, 355, 452
- Moore, Gordon, 258
- Moore, Michael, 55*nd*
- Moore's Law, 164, 169
- Mooseker, Mark, 203–204
- Morgan, Thomas Hunt, 202, 451
- Moriarity, Branden, 311–312
- Morrissey, Mike, 207
- Morrow, Jon, 203–204
- Mosunetuzumab-axgb (Lunsumio), 91
- Motulsky, Arno, 154
- mRNA vaccines, 362, 363*b*, 366–372, 374–377, 379
- MSH2* gene, 180
- MTM1* gene, 281–282
- Mucopolysaccharidosis type 1 disease (MPS 1), 238
- Mullen, James, 332
- Mulligan, Richard, 296, 296*ne*, 301
- Mullis, Kary, 23, 23*ngg*, 453
- Multiclonal T cells (MTCs), 310–311
- Multiple myeloma, 68*na*, 69–70, 70*nc*, 150, 177, 287, 295, 306–307, 330, 398, 413*b*
- Multiple sclerosis (MS), 20–21, 71*nc*, 85, 105, 154–156, 155*noo*, 228, 228*nr*, 233, 238*nj*, 410, 437
- Munroe, David, 147*nbb*, 169, 171*ni*
- Murphy, Andrew, 87*b*
- Murray, Joseph, 274*nc*, 452
- Murray, Ken, 8, 63, 352
- Muscarinic receptors, 129–130, 129*nz*, 225
- Musunuru, Kiran, 339
- Myelodysplastic syndrome (MDS), 68*na*, 69–70, 70*nc*, 261, 306–307
- Myers, Gene, 186*b*
- Myers, Peter, 223
- Myers, Rick, 22, 153, 194
- Mylotarg (gemtuzumab ozogamicin), 89
- Mylovenge, 298
- Myozyme, 238
- Myriad Genetics, 152–153
- N**
- N*-acetylgalactosamine (GlcNac), 266
- N*-methyl-D-aspartate (NMDA) receptor antagonists, 108*nq*
- Naldini, Luigi, 244, 275, 280
- Natalizumab (Antegren), 105
- Nathans, Daniel (Dan), 180, 403, 451
- National Cancer Institute (NCI), 82, 86, 300, 304, 310, 405*b*
- National Cooperative Drug Discovery Group (NCDDG), 86
- National Enterprise Board (NEB), 28–29
- National Institute for Allergy and Infectious Diseases (NIAID), 374
- National Institutes of Health (NIH), 6–7, 177, 177*no*
- National Research Development Corporation (NRDC), 28
- National Resilience, Inc., 240
- Natural killer (NK) cells, 266*nq*, 311–312, 311*b*, 329
- Nebacumab (Centoxin), 77–79, 435
- Negulescu, Paul, 235*nb*
- Nelsen, Robert (Bob), 132, 339, 341*b*, 427
- Nelson, Karen, 83
- NemaPharm, 146*ny*, 207–210
- Neon Therapeutics, 371
- Neozyme, 238
- Nerve growth factor (NGF), 115
- NEUPOGEN, 55, 61
- Neuraminidase (N or NA), 357–358
- Neurimmune, 105
- Neurocrine Biosciences, 126–127, 127*nv*, 225, 289
- Neurodegeneration, 104–105, 293
- Neuromuscular disease, gene therapy for, 281–282
- Neuropathic pain, 241
- Neurophth Therapeutics, 279*b*
- New drug applications (NDAs), 131, 437
- New England Biolabs, 24, 404
- Newman, Janet, 216, Pl18
- NeXagen, 56–57, 267
- NeXstar Pharmaceuticals, 259, 267–268
- Next-generation sequencing (NGS), 163, 163*na*, 166–170
- NGF (nerve growth factor), 115
- NHEJ (nonhomologous end joining), 335
- Nilotinib, 222
- Nippon Roche, 58
- Nirenberg, Marshall, 2, 164*nc*, 173, 451
- Nivolumab (Opdivo), 101–103, 412*b*
- Nkarta, 311*b*
- NMDA (*N*-methyl-D-aspartate) receptor antagonists, 108*nq*
- Nobel prizes, 403–404, 451–454
- Non-Hodgkin's lymphoma (NHL), 85, 91, 295, 303–306, 304*nq*, 307
- Non-small cell lung cancer (NSCLC), 100, 103
- Nordin, Albert (Al), 69*b*
- Norton, Larry, 88, 89*nw*
- Nossal, Sir Gustav (Gus), 296*b*, 296*nd*
- Notch* gene, 203–204

- Notch pathway, 203, 206  
Nova, Tina, 76  
Novak, Rodger, 330  
Novartis, 65, 76, 109, 190, 222,  
256, 263–265, 288*b*, 305,  
333–334, 360  
Novartis Institutes for BioMedical  
Research (NIBR), 225  
Novartis Venture Fund, 432  
Novasite, 223, 224–225, 336,  
407*b*  
Novavax, 364  
Novo Nordisk, 32, 266, 288*b*,  
392, 409*b*  
Nowinski, Robert (Bob), 57*nh*,  
80, 82–84, 120–121, 120*nl*  
Nuclear hormone receptors, 123  
Nucleic Acids Gordon  
Conference (1973), 4  
Nurse, Paul M., 189*b*, 452  
Nusinersen (Spinraza), 256,  
292*nn*  
Nuvaxovid, 365  
Nuvigil, 127  
Nvelop Therapeutics, 341*b*
- O**  
Obenshain, Andrew, 306  
Obesity, 148–149  
Ochoa, Severo, 18, 451  
OKT3 (muronomab-CD3), 72  
Olaparib (Lynparza), 153  
Old, Lloyd, 80, 97  
Oligonucleotides (oligos), 115,  
249–2250, 253–257, 259,  
263, 267–268, 270  
Olson, Maynard, 183  
Omapro, 128  
Omega Funds, 433  
OMIM (Online Mendelian  
Inheritance in Man)  
database, 242  
Onasemnogene abeparvovec-xioi  
(Zolgensma), 256  
Oncogen, 82–84  
Oncolytic virus therapy, 125  
Ondansetron, 113  
O’Neill, Gilmore, 332, 332*np*  
Ono, 102  
Onpattro (patisiran), 264  
Onyx Pharmaceuticals, 64,  
124–125, 396  
Opdivo (nivolumab), 101–103,  
412*b*  
Operation Warp Speed, 365, 374  
OrbiMed, 432–433  
Orbital Therapeutics, 342*b*  
Orchard Therapeutics, 280–281  
Orencia, 84  
Orexin, 225  
Organ transplant rejection, 238  
Organon, 70, 100–101  
Orilissa (elagolix), 127  
Orkambi, 235  
Orkin, Stuart, 315, 319  
Ornithine transcarbamylase  
(OTC) deficiency, 277  
Orphan Drug Act, 237, 423  
Ortho Pharmaceutical, 72  
Oscient, 136*b*  
Oseltamivir (Tamiflu), 259  
OSI Pharmaceuticals, 260,  
260*wk*  
Osteoporosis, 144  
Otrferlin (*OTOF*) gene, 293  
Otsuka, 218  
Owen-Jones, Lindsay, 360*b*  
Oxbryta, 287, 288*b*  
Oxford Biomedica, 366  
Oxford GlycoSciences, 33  
Oxford Nanopore Technologies,  
172  
Ozanimod, 228
- P**  
*p53* gene, 21–22, 152  
Pacific Biosciences, 171, 171*nj*  
Palbociclib (Ibrance), 125  
Palese, Peter, 361  
Paley, Bill, 35  
Palivizumab (Synagis), 72, 74,  
361–362  
Palynziq (phenylalanine  
ammonia-lyase), 238*b*  
Panitumumab (Vectibix), 75, 297  
Panorex, 79  
Papadopoulos, Stelios, P117,  
120–121, 120*nl*, 203–204,  
206, 219, 220*wk*, 253,  
368*nq*, 387, 420–422, 434  
Parainfluenza virus 3, 361  
ParAllele BioScience, 145*b*  
Pardoll, Drew, 295, 297  
Parkinson’s disease (PD), 105,  
129, 132–133, 157, 194,  
264, 289, 289*nm*  
PARP (poly ADP-ribose  
polymerase) inhibitors,  
153, 413  
Parshall, Lynne, 252, 263  
Parvovirus-based vector, 279*nc*  
Pasteur, Louis, 348  
Pasteur Institute, 352–353  
Patent, 19, 22, 32, 38–40, 46–  
47, 47*ngg*, 47*nhh*, 54, 64,  
72–73, 78, 87*b*, 98, 119,  
182, 182*nw*, 254–255,  
326–327, 352–353, 435  
Patent cliff, 413  
PathoGenesis, 65  
Patisiran (Onpattro), 264  
Patinos, Aristides (Ari), 191  
Paul, Steven (Steve), 129, 289  
Paxlovid, 261, 413  
pBR322 plasmid, 12  
PCSK9 (proprotein convertase  
subtilisin/kexin type 9),  
118–119, 119*ni*, 265,  
339–340  
PD-1, 99–102, 330  
PD-L1, 99–103  
Peat, Tom, 216, P118  
Pembrolizumab (Keytruda), 70,  
99–100, 102–103, 330,  
412*b*, 413  
Penhoet, Edward (Ed), 63  
Pennica, Diane, 39  
Perceptive Advisors, 433  
PerkinElmer, 184–185, 185*b*  
Perkins, Thomas, 9, 424  
Perlman, Andrew, 394*b*  
Perlmutter, Roger, 100, 369  
PerSeptive Biosystems, 185,  
185*nb*, 427  
Pershing Square, 434  
Perutz, Max, 285*ng*, 453  
Pestka, Sidney, 18–19  
Peters, Robert (Rob), 211,  
244–245, 288*b*, 425  
Petrou, Steven (Steve), 242,  
242*np*  
Pfizer, 30, 44, 56, 90, 126,  
128–129, 175*b*, 209, 261,  
283, 308, 360, 362, 365*b*,  
371, 374–375, 397, 413,  
413*b*, 435  
Pfizer Ventures, 432  
Phage display libraries, 74–75, 97  
Pharma-based VC Funds,  
431–432  
Pharmacia-Upjohn, 44, 48, 190,  
425  
Pharmacyclics, 192, 412*b*  
Pharmasset, 260–261, 411, 420  
Pheno Therapeutics (Pheno  
Tx), 410  
Phenylalanine ammonia-lyase  
(Palynziq), 238*b*  
Phenylketonuria (PKU), 238*b*  
Philadelphia chromosome, 221*b*,  
221*f*  
Phosphodiesterases (PDEs), 115,  
121–122  
Phosphoramidite chemistry,  
53*na*  
PhRMA, 423  
Physiome, 215*nd*



474 Index

- PIKfyve (phosphoinositide kinase, FYVE-type zinc finger containing), 133–134
- Pirfenidone, 411
- piRNAs, 342
- Plasmids, 2, 3, 3*f*, 341*nu*
- Platelet-derived growth factor (PDGF), 86
- Plum Island Animal Disease Center, 27
- PNH (paroxysmal nocturnal haemoglobinuria), 245
- Pojasek, Kevin, 311–312
- Poliovirus, 36*nt*, 350–352
- Pollack, Andrew, 219
- Poly (ADP-ribose) polymerase (PARP) inhibitors, 153, 413
- Polyclonal antibodies, 68*na*
- Polymerase chain reaction (PCR), 23
- Pompe's disease, 238
- Ponatinib (Iclusig), 177, 222, 222*ni*
- Pops, Richard, 394*b*
- Porter, Michael, 407
- Porter, Rodney, 67, 451
- Porton Down, 12–13, 12*ns*
- Positional cloning, 135*nb*, 136*b*, 136*f*, 137–139, 142, 144, 180, 184
- Positive allosteric modulator (PAM), 129, 242
- Posner, Brian, 246
- Post, Leonard (Len), 124
- Poste, George, 122*no*, 179, 182, 216, 218*ng*, 220*nk*, 250
- PowderJect, 359–360
- PowderMed, 360–361
- Praluent (alirocumab), 118–119
- Pramlintide (Symlin), 122–123
- Praxis, 241–242, 362
- Prescription Drug User Fee Act (PDUFA), 423
- Presenilin genes, 209
- Prevail, 293
- Prevnar, 371
- Prime Medicine, 329, 338–339
- Principia Pharmaceutical, 182
- Product license application, 78
- Product time line, 441–449
- Progenitor, 154
- Programmed cell death in *C. elegans*, 207*ng*, 209
- Progranulin, 108–109
- Progressive multifocal leukoencephalopathy (PML), 21
- Proleukin, 23, 64–65
- Prospect Genomics, 220, 220*nk*, 426*nb*
- Prostate acidic phosphatase, 299
- Prostate cancer, 76, 92, 297–300, 397
- Prostate-specific membrane antigen (PSMA)-directed CAR T, 307
- PROTACs (proteolysis targeting chimeras), 396–398, 396*b*, 396*f*
- Protein Design Labs (PDL), 74
- Protein kinase C, 255
- Protein Sciences, 359
- Protein subunit vaccines, 363*b*, 364–365
- Proteolix, 396
- Proteolysis targeting chimeras (PROTACs), 396–398, 396*b*, 396*f*
- Protospacer-adjacent motifs (PAMs), 324–325, 325*f*, 336, 341*b*
- Protropin, 15, 78
- Proveng, 298–300, 299*nk*–299*nm*
- Prudential Assurance, 28
- PSA (prostate-specific antigen), 76
- Psoriasis, 109–110, 412*b*
- Ptashne, Mark, 33–36, 41–42
- PTC Therapeutics, 257, 269*b*, 289
- Pulmonary fibrosis, pirfenidone for, 411
- Pulmozyme, 411
- Purdue Pharma, 242
- Pyrosequencing, 167, 167*b*
- Pyrukynd (mitapivat), 288*b*
- Pyruvate kinase deficiency, 288*b*
- Q**
- Qalsody, 257
- Qdenga, 350
- Qsymia, 130*naa*
- Queen, Cary, 74
- Quest Diagnostics, 192
- Quirkle, Declan, PI30
- Quist, George, 1*na*
- R**
- RA Capital Management, 433
- Raab, Kirk, 85, 423, 435
- Rabies vaccines, 348
- Raf kinase, 124–125
- Rammensee, Georg, 372
- Ranitidine (Zantac), 113
- Rare diseases, 233–247, 233*na*, 235*nb*–235*nc*, 239*nk*–239*nl*, 243*nq*, 245*b*
- Ras pathway, 203, 209
- Rastetter, William (Bill), 85, 227, 425
- Rathmann, George, 45, 53, 53*zb*, 60, 84, 121, 298
- Ravina, Bernard, 289
- Read, Leighton, 361, 361*ni*
- Receptech, 61, 61*nr*
- Recombinant DNA Advisory Committee (RAC), 7
- Recombinant DNA guidelines, 6–7, 11
- Recombinant DNA technology (rDNA), 4–7, 28–31
- Recombinate, 44
- Recombination, homologous, 335
- Recombivax HB, 353
- Recursion Pharma, 229
- Reddy, Kiran, 241
- Reed, John, 246, 431
- Refacto, 44
- Regenerative medicine, 393–395
- Regeneron, 75, 87*b*, 92, 115–120, 195–196, 254, 265, 333–334, 376*b*, 412*b*, 413*b*
- Regulus Therapeutics, 266
- Reid, Clifford (Cliff), 169
- Reimers, Neils, 4*nf*
- Rejuvenate Bio, 395
- Relyvrio (AMX0035), 130–131, 131*nc*
- Remdesivir, 261
- Remicade (infliximab), 55, 79, 97–99, 98, 98*nc*, 436
- Renal cell carcinoma, 125, 207, 297
- Renton, Hollings, 64, 124
- ReoPro (abciximab), 79, 79*nn*
- Repatha (evolocumab), 119
- Repertoire Immune Medicines, 305*nt*, 310–311, 377*b*, 407*b*, 427
- Research and Development Limited Partnership (RDLP), 16, 61, 237
- Resilience, 240, 292
- Respiratory syncytial virus (RSV), 361–362, 364, 365*b*
- Restriction enzymes, 2, 24, 24*ni*, 404
- Restriction fragment length polymorphisms (RFLPs), 136*b*
- ResVax, 364
- Resveratrol, 394*b*
- Ret kinase inhibitor, 432

- Retinitis pigmentosa, 278  
Retinoblastoma, 125  
Retrotransposons, 342  
Retrovirus vectors, 275, 278,  
280, 286, 301  
Reverse transcriptase, 3b, 260*ni*,  
260*nl*, 342, 338  
Revlimid, 303, 412*b*  
Revlon, 89  
Reynolds, Sherry, 205, P117  
RFLPs (restriction fragment  
length polymorphisms),  
136*b*  
Rheostat, 194  
Rheumatoid arthritis, 84, 98–99,  
118, 119*nj*  
Rhodes, Jane, 134  
Rhodopsin, 225  
Rhône-Poulenc Rorer, 252  
Ribopharma, 262  
Ribometrix, 269*b*  
Rice, Charles M., 453  
Richards, Brian, 33*b*  
Richardson, William (Bill), 219  
Richardson-Merrell, 29, 29*ng*  
Richmond, Mark, 141  
Riddell, Stan, 301, 305  
Rigby, Peter, 30–31  
Riggs, Art, 11, 72–73  
Riloncept (Arcalyst), 117, 118*b*  
Rink, Timothy (Tim), 122*no*  
Rinvoq (upadacitinib), 412*b*,  
412*nn*  
Riordan, John, 137–138  
Riordan, Michael (Mike),  
257–261, P123  
Risankizumab (Skyrizi), 109,  
109*nt*, 411*b*–412*b*, 412*nn*  
Risdiplam (Evrysdi), 257  
Rituximab (Rituxan), 76, 84–86,  
425  
Ritz-Carlton meeting, 420  
Rivière, Isabelle, 304  
RNA, 2, 3*b*, 262–266, 269*b*–  
270*b*, 320, 325–326,  
334–335, 338, 340,  
391–392  
RNAi (RNA interference), 210,  
210*nl*, 262–266  
RNARx, 367*no*  
Robbins, Frederick, 351, 451  
Robbins-Roth, Cynthia, 422*b*  
Roberts, Rich, 187, 187*nhh*, 452  
Robinson, David, 123  
Robinson, Robert, 142, 438,  
453  
Roblin, Richard (Rich), 273  
Roche, 171, 195, 264, 266, 280,  
411, 414, 435  
Roche Institute of Molecular  
Biology, 18, 20, 23, 64,  
93, 148  
Rock Springs Capital, 434  
Rocket Pharma, 291  
Roctavia (valoctogene  
roxaparvovac), 283–284  
Rodbell, Martin, 452  
Rogers Park, 405, 405*ng*  
Roizman, Bernard, 361  
Rondo, 92  
Rosen, Craig, 182  
Rosenberg, Steven (Steve), 64,  
300, 310  
Rosenthal, Arnon, 108  
Roses, Allen, 137  
Rosetta, 133  
RoseTTAFold, 228  
Ross, Mike, 15, 17*ncc*, 430  
Rossi, Derrick, 333, 366–368  
Rothberg, Jonathan, 166–167,  
170, 170*nh*, 203  
Rothman, James (Jim), 390*b*,  
452, 146–147, 147*nz*  
Rothschild, Victor, 54, 59  
Rous sarcoma virus (RSV), 249,  
249*na*  
Roux, Émile, 348  
Royal Free Hospital, 42  
Royston, Ivor, 76, 84  
Rozen, Issi, 341*b*  
*RPE65* gene, 278–279  
Rubens, Jacob (Jake), 342, 390*b*  
Rubin, Gerry, 188, 203–205,  
205*nd*, P117  
Rubius Therapeutics, 395  
Rumsfeld, Donald, 258  
Rutter, Bill, 11–13, 14, 63, 220,  
220*nk*, 316, 352  
Rybrevant (amivantamab), 92
- S**  
Sabatini, David, 203  
Sabin, Albert, 351  
Sadelain, Michel, 301, 304  
Sahin, Ugur, 370  
SAIC-Frederick, 405*b*  
Salk, Jonas, 351  
Salk Institute, 351–352  
Salmeterol, 113  
Salser, Winston, 45, 53  
Sambrook, Joseph (Joe), 34,  
38, 40  
Samuel, Harold, 405  
Sana Biotechnology, 390, 390*b*  
Sand Hill Rd., 424, 424*nz*  
Sanders, Charles, P123  
Sandoz, 37, 276  
Sandrock, Al, 428  
Sangamo Biosciences, 244, 283,  
316–321, 318*b*, 334  
Sanger, Fred, 10, 164, 403, 453  
Sanger Centre, 184, 187, 189  
Sanger sequencing, 164, 165*b*,  
174  
Sanghera, Gordon, 172  
SangStat, 238  
Sankyo (Daiichi-Sankyo), 31–32  
Sanofi, 45, 71*ne*, 75, 93,  
119–120, 119*nj*, 236, 237,  
238*nj*, 239, 246–247, 265,  
289, 308*b*, 359, 413*b*, 436  
Sanofi-Pasteur, 350*b*, 351  
Sanofi Ventures, 432  
Sarepta Therapeutics, 290–291  
Sarilumab (Kevzara), 118, 119*nj*  
Sarissa Capital, 434  
SARS-CoV-1, 223, 362, 373  
SARS-CoV-2, 120, 261, 274*nb*,  
347, 354*b*, 363–377,  
374*nw*, 376*b*, 377*b*,  
378*b*–379*b*, 379, 413, 413*b*  
Sato, Gordon, 86  
Sato, Vicki, 235, 341*b*, 427  
Scangos, George, 125, 206, 376*b*,  
434, 434*fff*, 437  
Schaefer, Ray, 8  
Schaller, Heinz, 8, 13  
Schally, Andrew, 22  
Scheinkein, David, 339  
Schekman, Randy, 390*b*, 452  
Schenk, Dale, 105  
Schenk, Tom, 87*b*  
Schenkein, David, 341*b*  
Schering AG, 20  
Schering-Plough, 19, 20, 49, 62,  
101, 435  
Schiller, John, 356  
Schimmel, Paul, 262–263, 394*b*  
Schizophrenia, 129–130  
Schlessinger, Joseph (Joe), 125*nr*  
Schliefer, Leonard (Len),  
115–117, 115*nf*  
Schmergel, Gabriel (Gabe), 35,  
35*nr*, 37, 37*nu*, 41, 417  
Schmidt, Benno, 35, 258, 424  
Schoemaker, Hubert, 77  
Schroder Ventures, 430–431  
Schrum, Jason, 368  
Schultz, George, 258  
Schuth, Alexander (Alex), 132  
Schwinn, Ken, P118  
Sclavo, 359  
SCN2A, 241–242  
SCN8A, 241–242  
Scolnick, Edward (Ed), 82  
Scott, Randy, 174  
Screening organisms, 114, 114*nc*

## 476 Index

- Seaborg, Glenn, 258, 258*ng*, 453  
Seagen, 83  
Searle, G.D., 29, 29*ne*, 33*b*,  
54, 64  
Seattle Genetics (Seagen), 90  
Secukinumab (Cosentyx), 109  
Seeburg, Peter, 12, 12*nr*, 13, 14  
SELEX (Systematic Evolution of  
Ligands by EXponential  
enrichment), 57, 267–268  
Senter, Pete, 83  
Sepsis, 77–79  
Septerna, 226–227  
Sequana, 75, 76, 120, 142–147,  
148*nf*, 150–151, 208–210,  
407*b*, P111, P127  
Sequencing by synthesis, 168,  
168*b*  
Sera Labs, 71  
Serono, 21*nee*, 31  
Sessler, Jonathan, 412*b*  
Severe combined  
immunodeficiency  
(SCID), 276, 278,  
280–281  
Severino, Michael, 342  
Sexton, Patrick (Pat), 227  
Sexually transmitted diseases,  
diagnostic tests for, 81,  
83–84  
Shapiro, Lawrence (Larry), 213,  
215, 217, 217*nf*  
Sharp, Phillip (Phil), 7–8, 36*b*,  
262, 452  
Sharpless, K. Barry, 454  
Shawver, Laura, 308*b*  
Shepherd, John, 341*b*  
Sherwin, Steven (Steve), 297,  
297*nf*  
Shimomura, Osamu, 453  
Shine, John, 14  
Shire Pharmaceuticals, 245*b*, 319  
Shoemaker, Chuck, 36*b*  
Shooter, Eric, 115–116  
Shoreline Biosciences, 266*nq*,  
311*b*  
Shotgun sequencing, 180,  
185–186, 185–188,  
185*ndd*, 186*b*  
Shreeve, James, 183  
Shriver, Kathy, 83  
shRNA, 320  
SIBIA, 87*b*  
Sickle cell disease (SCD), 233,  
285–288, 286*b*, 315, 319,  
320–321, 330–334, 335,  
337, 339  
Siegal, Clay, 90  
Sigal, Elliot, 154  
Sigal, Irving, 154*nm*  
Šikšnys, Virginijus, 324, 327,  
327*nk*  
Siliq (brodalumab), 109  
Simms, John, 59*nn*, 61  
Simon, Melvin (Mel), 187  
Sinclair, David, 394*b*, 394*zh*  
Singer, Maxine, 5  
Singh, George, 115  
Single-guide RNA (sgRNA), 326  
Single-Molecule Real-Time  
(SMRT) sequencing  
system, 171  
Single-nucleotide polymorphisms  
(SNPs), 136*b*  
Singular Genomics, 173*b*  
Sinovac Biotech, 363  
Sipuleucel-T (Provenge), 298,  
299*nk*–299*nm*  
siRNA, 262–266, 334  
Sirna Therapeutics, 263–264  
Sirtris Pharmaceuticals, 394*b*  
Skehel, John, 357*b*, 361  
Skolnick, Ed, 241  
Skolnick, Mark, 136*b*, 152  
Skunkworks projects, 30, 31*nj*,  
85, 167, 416  
Skyhawk Therapeutics,  
269*b*–270*b*  
Skyrizi (risankizumab), 109,  
109*nt*, 411*b*–412*b*, 412*nm*  
Slamon, Dennis, 87–89, 89*nw*  
Slaoui, Moncef, 374  
Sleep disorders, 127  
Small fibre neuropathy,  
240–241, 241*nn*  
Small molecules for RNA  
modulation, 269*b*–270*b*  
Smallpox, 347–348  
Smith, Chad, P118  
Smith, George P., 454  
Smith, Hamilton (Ham), 22,  
180, 403, 451  
Smith, Lloyd, 165  
Smith, Michael, 409*b*, 453  
Smith, Richard, 251, 255  
Smith, Wilson, 357*b*  
Smithies, Oliver, 75, 452  
SmithKline Beecham (SKB),  
179, 250, 353–354, 361  
SNP chips, 145, 145*b*  
Snyder, Michael (Mike), 203  
Sodium ion channel proteins,  
240–242  
Sofosbuvir (Sovaldi), 260, 411  
Solexa, 168, 168*b*, 169*ng*  
Soliris (eculizumab), 245*b*  
Soll, Dieter, 5  
Soll, Larry, 56  
SomaLogic, 56–57, 268–269,  
268*nr*  
SOMAmers (Slow Off-rate  
Modified Aptamers), 57,  
268  
SomaScan platform, 268–269  
Somatix Therapy, 296  
Somatostatin, 11, 13  
Sontheimer, Erik, 333  
Sorafenib (Nexavar), 125  
Soriot, Pascal, 368  
Sosei, 225  
Sotrovimab, 376*b*  
South Sea Bubble, 383,  
383*b*–384*b*  
Sovaldi (sofosbuvir), 260, 411  
SPAC (special purpose  
acquisition company), 269  
Spanish flu pandemic, 357, 357*nf*  
Spark Therapeutics, 279–280,  
283–284  
Spector, Arlen, 423  
Sphingosine-1-phosphate  
receptors, 227–228  
Spikevax, 413*b*  
Spinal muscular atrophy (SMA),  
255–257, 256*b*, 269*b*,  
292*nn*, 437  
Spinraza (nusinersen), 256,  
292*nn*  
Springer, Tim, 367, 367*np*  
Srinivisan, Chandrasegaran  
(Chandra), 316  
St. John, Tom, 122  
Stafford, Jack, 48  
Stampacchia, Otello, 433  
Standard Biotoools, 269  
Stanford University, 4, 4*nf*, 30,  
60, 77  
Starr, Kevin, 426  
State University of New York  
(SUNY) at Stony Brook,  
21, 36, 36*nt*  
Stebbing, Nowell, 54  
Stefánsson, Kári, 154–155, P112,  
P113  
Stein, Robert (Bob), 123, 177  
Steinberg, Wally, 177–179,  
179*ns*, 204, 298, 362  
Steinman, Lawrence (Larry), 126  
Steinman, Ralph, 298, 298*ni*, 452  
Stem cells, 274, 286–287, 291,  
423  
Stemmer, Willem P.C. (Pim),  
210–211  
Stephenson, Thomas (Tom), 145  
Stevens, Raymond (Ray), 218,  
227, 228  
Stewart, Martha, 86

- Stimulon, 365*b*  
Stoker, Sir Michael, 30  
Stratagene, 405*b*  
*Streptococcus pyogenes*, 326  
*Streptococcus thermophilus*, 324  
Strimvelis, 280–281  
Strober, Samuel (Sam), 297  
Structure-based drug design,  
213, 218, 225–227, 411,  
421, 423, 437  
Structural genomics, 213–230,  
225*np*  
Structural GenomiX (SGX),  
76*nj*, 213–223, 219,  
219*nh*, 219–222, 407*b*,  
419, 426*nb*, P118, P119  
Structural Therapeutics, 228  
Structure prediction using AI,  
228–230  
Stylli, Harry, 233  
Sudarsky, Jerry, 406  
Südhof, Thomas, 390*b*, 452  
Sugen, 125, 125*nr*, 425  
Sulston, John, 187, 189, 207*ng*,  
452  
Sumatriptan, 113, 233  
Sumitomo Chemicals, 115–116  
Sunitinib (Sutent), 125*nr*, 425  
Suntory, 40  
Superoxide dismutase (SOD),  
255, 257  
Sutimlimab (Enjaymo), 246,  
433  
Sutton, Granger, 186*b*  
SV Health Investors, 15, 17*nc*,  
108, 194, 227, 240, 243,  
266*nq*, 269*b*, 311–312,  
360, 410, 430–431  
SV40 T antigen, 21–22  
Swag, 417–418, P110  
Swanson, Robert (Bob), 8–9,  
16–17, 424  
Sykes, Sir Richard, 122, 135, 141,  
141*nn*  
Symdeko, 235  
Symlin (pramlintide), 122–123  
Synagis (palivizumab), 72, 74,  
361–362  
Synchrotron, 219, 219*nh*  
Synergen, 56–57  
Syntex, 80, 82–84  
Synthetic Genomics, 193  
Synthorx, 308*b*  
Syntonix, 44  
Syrrx, 218, 220, 223*no*  
Systemic lupus erythematosus  
(SLE), 182  
Syva, 80  
Szostak, Jack, 258, 267, 452
- T**  
T. Rowe Price, 434  
T-cell bispecific antibodies,  
91–93  
T-cell engagers, 310*b*  
T-cell expansion protocols, 302  
T-Cell Factory B.V., 304  
T-cell receptor (TCR), 300*nn*,  
301, 304, 309  
T cells, 296*b*, 300*b*, 301,  
310–311, 337–338  
T regulatory cells (Tregs), 300*b*  
T4 DNA polymerase, 267  
Tadalafil (Cialis), 122  
Takeda Pharmaceuticals, 151,  
222, 223*no*, 245*b*, 297,  
297*ng*, 309*b*–310*b*,  
350, 436  
Takeda Ventures, 431  
TALENs (TALE nucleases), 315,  
325*f*, 332*b*, 334  
Taltz (ixekizumab), 109  
Tam, Milton (Milt), 83  
Tamiflu (oseltamivir), 259  
Taniguchi, Tadasugu (Tada), 19  
Tanzi, Rudolph (Rudi), 130*naa*  
*Taq* polymerase, 23  
Tarceva (erlotinib), 260  
Tardive dyskinesia, 127  
Tate, Christopher, 225  
Tate, Simon, 240  
Tau, 104, 108*nq*  
*TBK1* gene, 194  
TCR (T-cell receptor), 300*nn*,  
301, 304, 309  
TCRT cells, 309  
Tebentafusp (Kimmtrak), 92, 93*b*  
Tecartus (brexucabtagene  
autoleucel), 304, 306  
Technology Development  
Capital (TDC), 28  
TeGenero, 92  
Tegtmeyer, Peter, 21  
Teitelman, Robert, 80, 82  
Temin, Howard, 4*nd*, 260*nl*,  
451  
TeneoBio, 91–92  
Tenofovir (Viread), 260  
Tepper, Bob, 426  
Termeer, Henri, 35*nr*, 236,  
236*nh*, 369, 417, 423,  
420*nv*  
Tessera Therapeutics, 341–343  
Tessier-Lavigne, Marc, 132  
Teva Pharmaceutical Industries,  
128  
Tezacaftor, 235  
Thatcher, Margaret, 70  
Theiler, Max, 348–349, 451
- Theophylline, 267  
Thermo Fisher Scientific, 145*b*,  
404, 404*b*–405*b*, 405*nf*  
Third-generation sequencing,  
170–172  
Third Rock Ventures, 385, 426,  
428  
Thoenen, Hans, 116  
Thomas, Don, 274*nc*  
Thomas, E. Donnall, 452  
Thrombin inhibitor, 265  
Thymoglobulin, 238  
Thymus, 296*b*  
Thyrogen, 238  
Tiagabine (Gabitril), 127  
TIGR (The Institute for  
Genomic Research),  
178–181, 184*naa*, 185,  
185*ndd*  
Tiollais, Pierre, 352  
Tisagenlecleucel (Kymriah),  
305–306  
Tissue plasminogen activator  
(t-PA), 16, 16*nx*, 30–31,  
38–40  
Tixagevimab/cilgavimab  
(Evusheld), 376*b*  
Tjian, Bob, 22, 153, 194, 318  
TKT (Transkaryotic Therapies),  
237, 237*ni*  
Tmunity Therapeutics, 307  
TNKase (Tenecteplase), 40  
Todaro, George, 82–83  
Todd, John, 142  
Tofersen, 257  
Toole, John (Jay), 366, 41, 259  
Top, Franklin, 362  
TOPO cloning, 404*b*  
TopoGenetics, 204–205  
Torque Therapeutics, 310, 427  
TOSCO, 54  
Tositumomab (Bexxar), 90  
Tovapadon, 129  
Tracey, Kevin, 98  
Tracr sequence, 324  
Transcription activation-like  
effectors (TALEs), 315,  
317*b*  
Transfusion-dependent  
 $\beta$ -thalassaemia (TDT),  
287, 319–320, 330–332,  
334, 337  
Transkaryotic Therapies (TKT),  
237, 237*ni*  
Transposons, 312, 341–342  
Transthyretin amyloidosis,  
333–334  
Transthyretin-mediated amyloid  
polyneuropathy, 257, 264

- Trbovic, Nikola, 430  
Tregs (T regulatory cells), 300*b*  
TREM2, 108, 109*b*  
Triangle Pharmaceuticals, 260  
Trigeminal neuralgia, 240–241  
Trikafta, 235, 413*b*  
Tristan da Cunha, 143, 145, P17, P18  
Triton Biosciences, 20  
Trk (kinase) inhibitor, 433  
Troxacitabine (Troxaryl), 223  
True North Therapeutics, 245–246  
Truvada, 260  
Tsien, Roger, 234, 453  
Ts'o, Paul, 250  
Tsui, Lap-Chee, 137–138  
Tubby protein, 217*nf*  
Tuddenham, Edward (Ted), 42, 283  
Tuerk, Craig, 267  
Tularik, 56, 91, 125, 125*nr*  
Tulip mania, 383, 383*b*  
Tumour-infiltrating lymphocyte (TIL) therapy, 64–65, 301, 310  
Tumour necrosis factor (TNF), 16, 62, 79, 97–99, 301  
Tumour suppressor genes, 152  
Türeci, Özlem, 370  
Turner, Lyle, 404*nd*  
Tuschl, Thomas, 262  
23andMe, 156–158, 157*b*  
2seventy bio Inc., 306–307, 306*nv*, 307*nw*  
Tyrosine kinase inhibitor, 412*b*  
Tysabri, 20, 105, 228*nr*
- U**  
Ubiquitin, 396*b*  
UCB, 33, 99  
Uhlén, Mathias, 166  
U.K. Biobank, 196  
Ulcerative colitis, 228  
Ullrich, Axel, 12, 12*nr*, 14, 88, 125*nr*  
Ulmer, Kevin, 9  
Ultima Genomics, 173*b*  
Ultragenyx, 283  
Umea, 328*nm*  
Unicorns, 388, 389–398, 390*b*, 391*ng*, 394*b*  
UniQure, 282, 283  
University of Birmingham, 21  
University of California Berkeley, 22, 326  
University of California Los Angeles (UCLA), 53, 89  
University of California San Diego (UCSD), 76, 86, 210, 234  
University of California San Francisco (UCSF), 8, 11–15, 63, 63*nu*, 303, 352–353  
University of Chicago, 45  
University of Colorado, 53, 56–57, 56*nf*  
University of Pennsylvania, 301, 305, 308*b*, 367, 367*no*, 371  
University of Queensland, 355–356  
University of Washington, 42, 53, 60, 82–83, 186  
Upadacitinib (Rinvoq), 412*b*, 412*nm*  
Upstaza (eladocagene exuparvovec), 289  
Urnov, Fyodor, 318  
U.S. Venture Partners, 54  
Ustekinumab (Stelara), 109  
Uveal melanoma, 93*b*
- V**  
Vabysmo (faricimab), 94  
Vaccination, 347–348  
Vaccines, 63, 274*nb*, 296, 347–380, 348*na*, 349*b*, 350*b*, 354*b*, 356*nc*, 357*b*, 363*b*, 365*b*, 374*nw*, 380*nz*, 413, 413*b*  
Vaccitec, 365–366, 374–375, 374*nw*  
Vagelos, Roy, 117  
Valbenazine (Ingrezza), 127  
Vale, Wylie, 126  
Valeant, 299  
Valenzuela, Pablo, 63, 352  
Valneva, 364, 364*nk*  
VanBeuzekom, Minka, 208, 210  
Vardi, Nathan, 192*noo*  
Variolation, 347  
Varmus, Harold, 82, 88, 124, 154, 177, 258, 452  
Vascular endothelial growth factor (VEGF), 94, 117, 118*b*, 264, 267, 368–369  
Vascular endothelial growth factor (VEGF) trap, 412*b*  
Vectibix (panitumumab), 75, 297  
Vector vaccines, 363*b*, 365–366  
Vehar, Gordon, 42  
Velcade (bortezomib), 150  
VelocImmune, 75, 117–118  
Vemurafenib, 206  
Venrock, 384, 425, 425*naa*  
Venter, Craig, 170, 173–174, 177–180, 178*nr*, 180*nu*, 183–192, 193, 202  
Venture capital, 8–9, 9*nj*, 15, 28, 35–36, 49, 54, 56, 59, 61, 76, 204–205, 215, 226, 310*nx*, 384–386, 389.  
*See also* Investors  
Vepdgestrant, 397  
Veracyte, 76  
Verdia, 211*b*  
Verge Genomics, 132–134  
Verily, 339  
Verma, Inder, 275  
Vernalis, 33*b*  
Vertex Pharmaceuticals, 196*b*, 210, 234–236, 235*nb*, 241, 292, 330–331, 413*b*, 432*ncc*, 436  
Verve Therapeutics, 329, 339–340  
Vesicular monoamine transporter type 2 (VMAT2), 127  
Vestar, 57, 267  
Vical, 277  
Vigil Neuroscience, 109*b*  
Viking Global, 434  
Villa-Komaroff, Lydia, 11  
VIR Biotechnology, 376*b*, 436  
Viracept, 213  
Viread (tenofovir), 260  
Vistide (cidofovir), 259  
Vitravene, 253  
Vivaldi, Rogério, 246  
Vixotrigine, 240  
VNV (Virus Not Virus), 341*b*  
Vogelstein, Bert, 103  
Von Maltzahn, Geoffrey, 342, 390*b*  
von Willebrand factor (vWF), 40–41, 44  
Voretigene neparvovec-rzyl (Luxturna), 279, 279*ne*  
Voyager Therapeutics, 127*nx*, 289–290  
Vutrisiran (Amvuttra), 264
- W**  
Wade, Nicholas, 19, 71, 343  
Waksal, Samuel (Sam), 86–87, 87*b*, 408*nk*  
Waldmann, Hermann, 71  
Walter and Eliza Hall Institute of Medical Research (WEHI), 61  
Warburg Pincus, 56  
Warrants, 80  
Waterfield, Michael (Mike), 86



- Waterston, Bob, 181, 187, 189  
Watson, James, 2, 39, 183–184,  
183*ny*, 424, 451  
Watts, Ryan, 131  
Webber, James (Jim), 186*b*  
Weinberg, Robert (Bob), 88  
Weintraub, Harold (Hal), 258  
Weir, Malcolm, 225  
Weissman, Charles, 8, 18–19,  
101*ng*  
Weissman, Drew, 308*b*, 342*b*, 367,  
367*nn*–367*no*, 403, 453  
Weissman, Irving (Irv), 261*nm*,  
296  
Wellcome, Henry, 189*b*  
Wellcome Research Laboratories,  
17, 38–40  
Wellcome Trust, 75, 184, 188,  
189*b*, 190–191  
Weller, Thomas, 351, 451  
Werth, Barry, 235  
Westphal, Christoph, 262, 394*b*  
Wexler, Nancy, 139  
Wheeze1 and 2/ASTH11 and J,  
144  
Whitcombe, Philip (Phil), 54  
White, Ray, 136*b*  
White, Tony, 184–185, 190  
Whitfield, Roy, 174  
Whitney, John Hay (Jock), 258,  
424  
Whole-exome sequencing,  
193–194  
Whole-genome sequencing, 180  
Whole-virus vaccines, 363–364,  
363*b*  
Wierenga, Wendell, 218, 220  
Wigler, Michael (Mike),  
35*nq*, 121  
Wilkins, Maurice, 451  
Willcocks, James (Spike), 172  
Williams, David, 320  
Williams, Doug, 240, 437, 373,  
416, 390, 409*b*  
Williamson, Alan, 218  
Williamson, Robert (Bob),  
135*na*, 137, 138*nf*  
Wilson, Richard, 31  
Wimmer, Eckard, 21, 36*b*, 36*nt*  
Winter, Sir Gregory (Greg), 74,  
89, 431, 454  
Wistar Institute, 70, 77  
Witte, Owen, 124  
Wojcicki, Anne, 157  
Wolfe, Josh, 341*b*  
Wolff, Jon, 367  
Wong, Gordon, 36*b*  
Wong, Liz, 41  
Woody, James (Jim), 98  
Wuhan, China, 378*b*  
Wyeth, 48–49, 415, 435  
X  
X-linked myotubular myopathy  
(XLMTM), 281–282  
X-ray crystallography, 214, 217,  
220*ni*, 226–227  
X-ray diffraction, 219, 226  
Xanthopoulos, Kleantis, 266,  
266*nq*, 311*b*  
Xarelto, 412*b*  
Xoma, 77–79  
XTEN technology, 211, 244  
Y  
Y combinator, 132  
Yamanaka, Shinya, 366*nm*,  
394–395, 452  
Yancopoulos, George,  
116–117  
Yanofsky, Charles, 62  
Yeast artificial chromosomes  
(YACs), 184  
Yellow fever, 348–349, 349*b*  
*Yersinia pestis*, 357*nf*  
Yogurt, 324  
Young, Keith, 339, 341*b*  
Young, William (Bill), 88, P11  
Z  
Zaffaroni, Alejandro (Alex), 62,  
210, 361*ni*  
Zamecnik, Paul, 249  
Zamel, Noe, 143  
Zantac (ranitidine), 113  
Zerhouni, Elias, 119–120, 246  
Zhang, Alice, 133  
Zhang, Feng, 325–328, 331,  
336, 341*b*  
Zika virus, 370, 388  
Zinc finger nuclease (ZFN), 316,  
317*b*–318*b*, 318–323,  
326, 326*ng*, 330, 334  
Zinc fingers, 315–317,  
317*b*–318*b*, 321*ne*, 323,  
325*f*, 328  
Zinder, Norton, 187  
Zinkernagel, Rolf M., 296*nd*,  
452  
Zolgensma (onasemnogene  
abeparvovec-xioi), 256  
Zuker, Charles, 210, 210*nk*  
zur Hausen, Harald, 355, 452  
Zydowsky, Lynne, 205  
ZymoGenetics (Zymo), 60, 408,  
409*b*, P128, P129  
ZZ Top, 416*no*